|
The purpose of this
course is to prepare healthcare professionals to adhere to
scientifically accepted principles and practices of infection control,
understand modes and mechanisms of transmission, understand the use of
engineering and work practice controls, select and use appropriate
barrier protections, create and maintain a safe environment, and prevent
and manage infectious and communicable diseases.
After completing this course, the
learner will be able to:
|
1. |
Discuss the responsibility
to adhere to scientifically
accepted infection control
standards and to monitor
subordinates, |
| |
|
|
2. |
Identify disease
transmission mechanisms and
strategies for prevention, |
| |
|
|
3. |
Discuss the use of
engineering and work
practice controls to
minimize exposure to
potentially infectious blood
borne pathogens, |
| |
|
|
4. |
Discuss the selection and
use of personal protective
equipment (PPE) and other
preventive barriers, |
| |
|
|
5. |
Identify cleaning,
disinfection and
sterilization standards for
creating and maintaining a
safe environment, and |
|
|
|
|
6. |
Discuss prevention and
management of infectious or
communicable diseases in
healthcare professionals. |
Healthcare professionals have an
obligation to adhere to
scientifically accepted standards
for infection control to prevent
disease transmission amongst
patients or between patients and
healthcare professionals. The
healthcare professional also has a
responsibility to monitor the
infection control practices of
subordinates. The state of New York
takes this very seriously. In fact
New York rules and regulations
require healthcare professionals to
participate in infection control and
barrier precautions education at
least every four years. Evidence of
completion of this training must be
submitted to the State Department of
Health or the Education Department.
Physicians with hospital privileges
will present the training
documentation to the hospital in
lieu of the Department of Health
during the process of renewal of
hospital privileges (NY, 2008).
New York professions required to
obtain this education are dental
hygienists, dentists, licensed
practical nurses, optometrists,
physicians, physician assistants,
podiatrists, registered professional
nurses and specialist assistants,
medical students, medical residents,
and physician assistant students
Exemptions may be granted because
the professional has completed
equivalent course work or because
the nature of his or her practice
does not require the use of
infection control techniques or
barrier precautions (NY, 2008). A
written application for exemption
from completion of this course work
must be presented to the Department
of Health for approval.
In New York, state rules and
regulations define responsibility
for compliance and consequences for
non-compliance with infection
control practices. All licensed
healthcare facilities are
responsible for monitoring and
enforcing proper use of infections
control practices and standard
precaution. Failure to comply can
result in a citation, potential
fines, and other disciplinary action
against the facility. Licensed
healthcare professionals who fail to
use appropriate infection control
techniques may be charged with
professional misconduct and
disciplinary action. Patient or
employee complaints about lax
infection control practices in
private offices will cause an
investigation by the Department of
Health and/or Education.
Substantiated lapses may result in
charges of professional misconduct
against licensed healthcare
professionals who were directly
involved, who were aware of the
violations, or who were responsible
for ensuring staff education and
compliance (NY, 2008).
Scientifically accepted infection
control techniques include but are
not limited to (NY, 1992, p D):
|
wearing appropriate
protective gloves at all
times when touching blood,
saliva, other body fluids or
secretions, mucous
membranes, non-intact skin,
blood-soiled items or bodily
fluid-soiled items,
contaminated surfaces,
sterile body areas, and
during instrument cleaning
and decontamination
procedures; |
| |
|
|
discarding gloves used
following treatment of a
patient and changing to new
gloves if torn or damaged
during treatment of a
patient; washing hands and
donning new gloves prior to
performing services for
another patient; and washing
hands and other skin
surfaces immediately if
contaminated with blood or
other body fluids; |
| |
|
|
wearing of appropriate
masks, gowns or aprons, and
protective eyewear or chin
length plastic face shields
whenever splashing or
spattering of blood or other
body fluids is likely to
occur; |
| |
|
|
sterilizing equipment and
devices that enter the
patient’s vascular system or
other normally sterile areas
of the body; |
| |
|
|
sterilizing equipment and
devices that touch intact
mucous membranes but do not
penetrate the patient’s body
or using high-level
disinfection for equipment
and devices which cannot be
sterilized prior to use for
a patient; |
| |
|
|
using appropriate agents
including but not limited to
detergents for cleaning all
equipment and devices prior
to sterilization or
disinfection; |
| |
|
|
cleaning, by use of
appropriate agents including
but not limited to
detergents, equipment and
devices which do not touch
the patient or that only
touch the intact skin of the
patient; |
| |
|
|
maintaining equipment and
devices used for
sterilization according to
the manufacturer’s
instructions; |
| |
|
|
adequately monitoring the
performance of all
personnel, licensed or
unlicensed, for whom the
licensee is responsible
regarding infection control
techniques; |
| |
|
|
placing disposable used
syringes, needles, scalpel
blades, and other sharp
instruments in appropriate
puncture-resistant
containers for disposal; and
placing reusable needles,
scalpel blades, and other
sharp instruments in
appropriate puncture
resistant containers until
appropriately cleaned and
sterilized; |
| |
|
|
maintaining appropriate
ventilation devices to
minimize the need for
emergency mouth-to-mouth
resuscitation; |
| |
|
|
refraining from all direct
patient care and handling of
patient care equipment when
the healthcare professional
has exudative lesions or
weeping dermatitis and the
condition had not been
medically evaluated and
determined to be safe or
capable of being safely
protected against in
providing direct patient
care or in handling patient
care equipment; and |
| |
|
|
placing all specimens of
blood and body fluids in
well-constructed containers
with secure lids to prevent
leaking; and cleaning any
spill of blood or other body
fluid with an appropriate
detergent and appropriate
chemical germicide. |
Definitions
|
Pathogen or infectious agent
is a biological agent
capable of causing disease. |
| |
|
|
Transmission is any
mechanism by which a
pathogen is spread by a
source of reservoir to a
person. |
| |
|
|
Reservoir is any person,
animal, plant, soil,
substance, or any
combination of these in
which an infectious agent
normally lives and
multiplies. The agent
depends on the reservoir for
survival and the reservoir
must provide a place where
the agent can reproduce
itself in such a manner that
it can be transmitted to a
susceptible host. |
| |
|
|
Susceptible host is a person
or animal lacking effective
resistance to a particular
infectious agent. |
| |
|
|
Common vehicle is
contaminated material,
product, or substance that
serves as an intermediate
means by which an infectious
agent is transported to two
or more susceptible hosts. |
| |
|
|
Colonization is when an
organism is present without
host interference or
interaction, like normal
skin flora. |
| |
|
|
Infection is when the host
resists and organism, like
redness or swelling, around
a skin tear. |
| |
|
|
Infectious disease is when
the infected host shows a
decline in wellness due to
an infection. |
| |
|
|
Incubation period is the
time between contact and
when the first symptom is
recognized. |
| |
|
|
Latency is the time after
primary infection during
which the microorganism
lives within the host
without producing clinical
evidence. |
Overview of Transmission
A chain of events is required for
infection to occur. These events are
a causative organism, reservoir for
the organism, a means to exit the
reservoir, a mode of transmission, a
susceptible host, and a mode of
entry into the host. Causative
organisms may be bacteria,
rickettsiae, viruses, protozoa,
fungi, or parasites. The
characteristics of causative
organisms are:
|
Pathogenicity: ability to
cause disease |
| |
|
|
Virulence: disease severity
and invasiveness (ability to
enter and move through
tissue) |
| |
|
|
Infectious dose: number of
organisms needed to initiate
infection |
| |
|
|
Organism specificity: host
preference |
| |
|
|
Antigen variations: viral
genetic recombinations |
| |
|
|
Toxogenicity: capacity to
produce toxins |
| |
|
|
Ability to develop
resistance to antimicrobial
agents |
The organism and its reservoir are
the source of infection. The
organism must have a means to exit
the reservoir. In an infected host
the organisms exits through the
respiratory tract, gastrointestinal
tract, genitourinary tract, or
drainage from a wound. A route of
transmission is necessary to connect
the source of infection to its new
host. Routes of transmission are
contact or airborne.
Contact transmission
|
Direct contact:
person-to-person |
| |
|
|
Indirect contact: usually an
inanimate object |
| |
|
|
Droplet contact: large
particles from coughing,
sneezing, or talking |
Airborne transmission
|
Droplet nuclei: residue of
evaporated droplets that
remain suspended in the air |
| |
|
|
Dust particles in the air
containing the infectious
agents |
The following table outlines the
organism, mode of transmission and
incubation period for most common
microorganisms and parasites (Smeltzer
& Bare, 2003), (Nettina, 2001).
|
Disease/Condition |
Organism |
Mode of Transmission |
Incubation Period |
|
Acquired immunodeficiency syndrome (AIDS) |
Human immunodeficiency virus |
Sexual
Percutaneous
Prenatal |
Median of 10 years |
|
Amebiasis |
Entamoeba histolytica |
Contaminated water
Contact with raw vegetables |
2-4
weeks |
|
Chancroid |
Haemophilus ducreyi |
Sexual |
3-5
days |
|
Chickenpox |
Varicella zoster |
Airborne |
14
days |
|
Cholera |
Vivrio cholera |
Ingestion of water contaminated with human waste |
A
few hours-5days |
|
Creutzfeldt-Jacob disease |
Prion proteinaceous |
Unknown in most cases |
15
months to 30 years |
|
Cryptococcosis |
Cryptococcus neoformans |
Probably by inhalation
No person-to-person spread |
Unknown |
|
Cyptosporidiosis |
Cryptosporidium species |
Ingestion of contaminated water
Direct contact with carrier |
Probably 1-2 days |
|
Cytomegalovirus (CMV) |
Cytomegalovirus |
Transfusion
Transplant
Sexual
Perinatal
Contact with mucus membranes |
Highly variable: 3-8 weeks after transmission
Newborn: 3-12 weeks after delivery
|
|
Diarrheal diseases |
Campylobacter species |
Ingestion of contaminated food |
3-5
days |
|
|
Clostridium difficile |
Fecal-oral
Efficient transfer by healthcare professionals
to patients |
Variable, in part related to the influence of
antibiotics |
|
|
Salmonella species |
Ingestion of contaminated food or drink |
12-36 hours |
|
|
Shigella species |
Ingestion of contaminated food or drink
Direct contact with carrier |
1-3days |
|
|
Yersinia species |
Ingestion of contaminated food or drink
Direct contact with carrier |
3-7
days |
|
Giardiasis |
Giardia lamblia |
Fecal-oral transmission
Ingestion of contaminated water or food |
1-4
weeks |
|
Gonorrhea |
Neisseria gonorrhea |
Sexual |
2-7
days |
|
Hand, foot, and mouth disease |
Coxsackie virus |
Direct contact with nose and throat secretions,
and with feces of infected persons |
3-5
days |
|
Foodborne hepatitis |
Hepatitis A |
Ingestion of contaminated food or drink |
A:
15-50 days |
|
Hepatitis E |
Direct contact with carrier |
E:
unclear |
|
Bloodborne hepatitis |
Hepatitis B |
Sexual |
B:
45-160 days |
|
Hepatitis C |
Perinatal |
C:
6-9 months |
|
Hepatitis D |
Percutaneous |
D:
Unclear |
|
Herpangina |
Coxsackie virus |
Direct contact with nose and throat secretions,
and with feces of infected persons |
3-5
days |
|
Herpes simplex |
Human herpesvirus 1 and 2 |
Contact with mucous membrane secretions |
2-12 days |
|
Histoplasmosis |
Histoplasma capsulatum |
Inhalation of airborne spores |
5-18 days |
|
Hookworms |
Necator americanus
Ancyclostoma deodenale |
Contact with soil contaminated with feces |
A
few week to many months |
|
Impetigo |
Staphylococcus aureus |
Contact with carrier |
4-10 days |
|
Influenza |
Influenza virus A, B, or C |
Droplet spread |
27-72 hours |
|
Legionnaires’ disease |
Legionella pneumonphila |
Airborne from water source |
2-10 days |
|
Listeriosis |
Listeria monocytogenes |
Perinatal
Sexual |
Unclear, probably 3-70 days |
|
Lyme disease |
Borrelia burgdorferi |
Tick bite |
14-23 days |
|
Lymphogranuloma venereum |
Chlamydia inguinale |
Sexual |
Weeks to years |
|
Malaria |
Plasmodium vivax
Plasmodium malariae
Plasmodium falciparum
Plasmodium ovale |
Bite from Anopheles mosquito |
12-30 days |
|
Measles |
Measles virus |
Droplet spread |
8-13 days |
|
Meningococcal meningitis or bacteremia |
Neisseria meningitidis |
Contact with pharyngeal secretions, perhaps
airborne |
2-10 days |
|
Mononucleosis |
Epstein Barr virus |
Contact with pharyngeal secretions |
4-6
weeks |
|
Mycobacterial diseases (non-tuberculosis)
Mycobacterium species |
Mycobacterium avium
Mycobacterium kansaii
Mycobacterium fortuitum
Mycobacterium gordonae
Other Mycobacterium species |
Variable: probably contact with soil, water, or
other environmental sources. Not transmissible
person-to-person |
Variable |
Mycoplasma
pneumonia |
Mycoplasma pneumonia |
Droplet inhalation |
14-21 days |
|
Pediculosis |
Pediculus humanus capitus (head louse)
Pediculus humanus corporis (body louse) |
Direct contact |
1-2
weeks |
|
|
Phthirus pubis (crab louse) |
Sexual |
1-2
weeks |
|
Pinworm |
Enterobius vermicularis |
Direct contact with egg-contaminated articles |
4-6
week life cycle
Often months of infection before recognition |
|
Pneumocystis pneumonia |
Pneumocystis carinii |
Unknown
Not transmitted person-to-person |
Infants 1-2 months
Adults unclear
|
|
Pneumococcal pneumonia |
Streptococcus pneumoniae |
Droplet spread |
Probably 1-3 days |
|
Rabies |
Rabies virus |
Direct contact of virus-laden saliva of a rabid
animal into a bite or scratch |
2-8
weeks |
|
Respiratory syncytial disease |
Respiratory syncytial virus |
Self inoculation by touching mouth or nose after
contact with infectious respiratory secretions |
3-7
days |
|
Ringworm |
Microsporum species
Trychophton species
Epidermophyton floccosum |
Direct and indirect contact with lesions |
4-10 days |
|
Rocky Mountain Spotted fever |
Rickettsia ricketsii |
Tick bite |
3-14 days |
|
Rotavirus gastroenteritis |
Rota virus |
Fecal, oral |
About 48 hours |
|
Rubella |
Rubella virus |
Droplet spread
Direct contact |
14-21 days |
|
Scabies |
Sarcoptes scabiei |
Direct skin contact |
2-6
weeks |
|
Staphylococci |
Staphylococcus aureus
Coagulase-negative:
S. epidermdidis
S. haemolyticus |
Direct contact with draining lesions
Auto-infection from colonized nares |
Variable, usually 4-10 days |
|
Streptococci |
Streptococcus
pyogenes groups A with about 80 serologically
distinct types |
Large respiratory droplets
Direct contact with secretions
Ingestion of contaminated food |
1-3
days |
|
Syphilis |
Treponema pallidum |
Sexual |
2-6
weeks |
|
Tetanus |
Clostridium tetani |
Puncture wound |
4-21 days |
|
Trichinosis |
Trichinella spiralis |
Ingestion of insufficiently cooked food,
especially pork and beef |
10-14 days |
|
Tuberculosis |
Mycobacterium tuberculosis |
Airborne |
4-12 weeks |
|
Typhoid fever |
Salmonella typhi |
Ingestion of contaminated food or water |
3
days to 3 months |
The host must be susceptible to the
infection for infection to occur.
Factors influencing susceptibility
are:
|
Number of organisms to which
host is exposed and the
duration of exposure |
| |
|
|
Age, genetic constitution of
host, and general physical,
mental, and emotional health
and nutritional status of
the host |
| |
|
|
Status of hematopoietic
systems; efficacy of
reticuloendothelial system |
| |
|
|
Absent or abnormal
immuglobulins |
| |
|
|
The number of T lymphocytes
and their ability to
function |
Pregnant healthcare professionals
are not known to be at greater risk
of contracting bloodborne
infections; however, during
pregnancy, the infant is at risk of
perinatal transmission.
The organism must have a portal of
entry into the host for infection to
occur. Portals of entry are the
mucous membranes, non-intact skin,
respiratory tract, gastrointestinal
tract, genitourinary tracts, or a
mechanism of introduction (percutaneous
injury or invasive devices).
Drug Resistant Staphylococcus
Aureus
Staphylococcus Aureus is
transmission primarily via the hands
of healthcare professional and by
direct contact with contaminated
equipment and surfaces. Transmission
is very efficient and Staphylococcus
Aureus colonizes the skin and nares
easily. Once colonized, the person
faces the likelihood of infection
when invasive procedures are
performed.
Methicillin and Oxacillin-Resistant
Staphylococcus Aureus (MRSA, ORSA)
are a common nosocomial infection in
hospitals and extended care
facilities. MRSA/ORSA colonization
is rarely recognized, so every
patient must be assumed to have been
exposed to MRSA/ORSA. MRSA/ORSA can
produce toxins and invade body
tissues. The only effective
antibiotic is vancomycin. Contact
precautions are not recommended by
the center for disease control
(CDC), but some facilities have made
it a policy.
Vancomycin Intermediate
Staphylococcus aureus (VISA) and
Vancomycin Resistant Staphylococcus
aureus (VRSA) are classified based
on lab test. The result of the test
is called minimum inhibitory
concentration (MIC), which is the
measure of the minimum amount of
antimicrobial agent that inhibits
bacterial growth in a test tube.
Staph bacteria are classified as
VISA if the MIC for vancomycin is
4-8µg/ml, and classified as VRSA if
the vancomycin MIC is >16µg/ml (CDC,
April, 2004). This infection must be
reported to the CDC and the state
department of health. Contact
precautions are required.
Vancomycin-Resistant Enterococcus
(VRE)
Enterococcus is a gram-positive
bacterium that is normal flora of
the gastrointestinal tract and
female genital tract. It is a
relatively weak pathogen, but if
infection occurs it is capable of
producing significant infection and
treatment options are limited. VRE
is transmitted primary via the hands
of healthcare professionals and
direct contact with contaminated
equipment and surfaces. Contact
precautions are required. Some
facilities are requiring a special
isolation where a gown and glove are
worn even if contact with the
patient is not expected. This is not
recommended by CDC.
Multidrug-Resistant Tuberculosis
(MDR-TB)
TB is caused by the bacteria,
mycobacterium tuberculosis. It is
one of the oldest recognized
infectious diseases. MDR-TB has
occurred in recent years due to poor
compliance or incomplete therapy
regimen. Airborne precautions are
required.
Drug-Resistant Streptococcus
pneumoniae
Streptococcus pneumoniae is a
leading cause of morbidity and
mortality in the United States. It
is community acquired and is
manifested in meningitis, bacteremia,
pneumonia and otitis media. The
elderly and the very young are the
most susceptible.
Penicillin-resistant and
multidrug-resistant strains have
begun to emerge and are widespread
in some communities. A vaccine for
the most common serotypes of S.
pneumoniae is available, but
underutilized.
Drug-Resistant Acinetobacter
Acinetobacter is bacteria usually
found in the soil, water, and on the
skin of healthy people. Susceptible
people are immunocompromised, have
chronic lung disease, or diabetics.
Outbreaks of pneumonia, wound
infections, and blood infections
occur in healthcare facilities where
very sick patients are housed, like
intensive care units. People on
ventilators, who have prolonged
hospital stays and who have open
wounds are at greater risk (CDC
September, 2004).
Controls are incorporated into the
healthcare work setting to avoid or
reduce exposure to potentially
infectious materials. Healthcare
associated transmission is the
transmission of microorganisms that
is likely to occur in a healthcare
setting that can be reduced by using
engineered controls, safe injection
practices, and safe work practices.
Engineering controls are equipment,
devices, or instruments that remove
or isolate a hazard. Safe injection
practices are equipment and
practices that allow the performance
of injections in an optimally safe
manner for patients, healthcare
providers, and others that reduce
exposure (CDC, 2008). Work practice
controls change practices and
procedures to reduce or eliminate
risks.
Standard precautions are strategies
for protecting healthcare
professionals from occupational
transmission of organisms. The
premise is that all pre-existing
patient infections cannot be
identified; therefore, barrier
precautions should be used routinely
to protect from all sources of
potential infection. Standard
precautions apply to nonintact skin
and mucous membranes, blood, all
body fluids, secretions, and
excretions, except sweat, regardless
of whether or not they contain
visible blood. Additional
precautions are based on highly
transmissible or epidemiologically
important pathogens. Transmission
Based Precautions (isolation) are
airborne, droplet, and contact.
New elements of standard precautions
have been added to focus on patient
protection. These elements are
respiratory hygiene/cough etiquette,
safe injection practices, and the
use of masks for insertion of
catheters of injections into spinal
or epidural spaces via lumbar
puncture (Siegel, Rhinehart,
Jackson, & Chiarello, 2007).
Respiratory hygiene/cough etiquette
is a strategy to reduce transmission
of respiratory infections at the
first point of entry into a
healthcare setting. Signs educating
patients and families should be
posted at entry areas. The
instructions are that persons with
cough, congestion, rhinorrhea or
increased respiratory secretions
should (Siegel, Rhinehart, Jackson,
& Chiarello, 2007):
|
Cover the mouth and nose
when coughing or sneezing
|
| |
|
|
Dispose of used tissues
promptly |
| |
|
|
Use a surgical mask if
coughing and if tolerated |
| |
|
|
Wash hands after contact
with respiratory secretions |
| |
|
|
Separate at least three feet
from persons with
respiratory infections in
common areas when possible.
|
Healthcare personnel should observe
Droplet Precautions when caring for
patients with signs and symptoms of
a respiratory infection. Healthcare
personnel who have a respiratory
infection are advised to avoid
direct patient contact, especially
with high risk patients. If this is
not possible, then a mask should be
worn while providing patient care
(Siegel, et.al. 2007).
Nurses sustained the largest
proportion of sharps injuries of all
healthcare professionals, but
laboratory staff, physicians,
housekeepers, and other healthcare
professionals are also injured
(Perry, Jagger & Parker, 2003). Some
of these injuries expose
professionals to bloodborne
pathogens that can cause infection.
The most important of these
pathogens are HBV, HCV, and HIV.
Infections with each of these
pathogens are potentially life
threatening and preventable.
One serious bloodborne infection can
cost more than a million dollars for
medications, follow up laboratory
testing, clinical evaluation, lost
wages, and disability payments. The
human costs after an exposure are
immeasurable. Employees may
experience anger, depression, fear,
anxiety, difficulty with sexual
relations, difficulty sleeping,
problems concentrating, and doubts
regarding their career choice. The
emotional effect can be long
lasting, even in a low risk exposure
that does not result in infection (Twitchell,
2003).
Percutaneous injuries can be avoided
by eliminating the unnecessary use
of needles, using devices with
safety features, and promoting
education and safe work practices
for handling needles and related
systems. Since 1993, the use of
safety-engineered sharps devices has
increased while the use of
conventional sharps devices has
decreased. Percutaneous injury rates
decreased dramatically (Perry, et.al.
2003). A number of sources have
identified the desirable
characteristics of safety devices.
These characteristics include the
following (NIOSH, 1999):
|
The device is needleless.
|
| |
|
|
The safety feature is an
integral part of the device.
|
| |
|
|
The device preferably works
passively (i.e., it requires
no activation by the user).
If user activation is
necessary, the safety
feature can be engaged with
a single-handed technique
and allows the
professional's hands to
remain behind the exposed
sharp. |
| |
|
|
The user can easily tell
whether the safety feature
is activated. |
| |
|
|
The safety feature cannot be
deactivated and remains
protective through disposal.
|
| |
|
|
The device performs
reliably. |
| |
|
|
The device is easy to use
and practical. |
| |
|
|
The device is safe and
effective for patient care.
|
Although each of these
characteristics is desirable, some
are not feasible, applicable, or
available for certain healthcare
situations. For example, needles
will always be necessary where
alternatives for skin penetration
are not available. Also, a safety
feature that requires activation by
the user might be preferable to one
that is passive in some cases. Each
device must be considered on its own
merit and ultimately on its ability
to reduce workplace injuries. The
desirable characteristics listed
here should serve only as a
guideline for device design and
selection.
Needles should NEVER be recapped,
bent, broken, or removed from
contaminated syringes. Recapping by
hand is prohibited under the OSHA
bloodborne pathogens standard [29
CFR 1910.1030] unless no alternative
exists. Sharps should be disposed
into a puncture-proof container.
There is exposure to percutaneous
injuries during procedures where
there is opportunity for
percutaneous exposure, especially
where there is poor visualization,
blind suturing, non-dominant hand
opposing or next to a sharp, and
exposure to bone spicules and metal
fragments. Sharp equipment should be
disassembled using forceps or other
devices. Suturing should always be
done with a needle holder, forceps,
or other tool. Do not use fingers to
hold tissue when suturing or
cutting. Never leave sharps on a
work field. If used needles or other
sharps are left in the work area or
are discarded in a sharps container
that is not puncture resistant, a
needlestick injury may result.
Injury may occur when a healthcare
professional attempts to transfer
blood or other body fluids from a
syringe to a specimen container
(such as a vacuum tube) and misses
the target.
Safe injection practice in hospitals
is well established. However,
outbreaks of HBV and HCV amongst
patients were traced back to
ambulatory care facilities, which
identified the need to define and
reinforce safe injection practices
in outpatient care setting. The
reuse of needles, multidose vials,
and work areas containing both
sterile and contaminated injection
supplies contributed to the problem.
There was a lack of understanding of
aseptic technique, a lack of
oversight, and failure to follow up
on infection control breeches (CDC,
2008). The following are safe
injection practices recommended by
CDC (2008, pg. 1) apply to the use
of needles, cannulas that replace
needles, and, where applicable
intravenous delivery systems.
|
Use aseptic technique to
avoid contamination of
sterile injection equipment.
|
| |
|
|
 |
Do not administer medications from a
syringe to multiple patients, even
if the needle or cannula on the
syringe is changed. |
|
|
|
 |
Needles, cannula and syringes are
sterile, single-use items; they
should not be reused for another
patient nor to access a medication
or solution that might be used for a
subsequent patient. |
|
|
|
|
Use fluid infusion and
administration sets (i.e.,
intravenous bags, tubing and
connectors) for one patient
only and dispose
appropriately after use.
|
| |
|
|
 |
Consider a syringe or needle/cannula
contaminated once it has been used
to enter or connect to a patient's
intravenous infusion bag or
administration set. |
|
|
|
|
Use single-dose vials for
parenteral medications
whenever possible. |
| |
|
|
 |
Do not administer medications from
single-dose vials or ampules to
multiple patients or combine
leftover contents for later use.
|
|
|
|
|
If multidose vials must be
used, both the needle or
cannula and syringe used to
access the multidose vial
must be sterile. |
| |
|
|
 |
Do not keep multidose vials in the
immediate patient treatment area and
store in accordance with the
manufacturer's recommendations;
discard if sterility is compromised
or questionable. |
|
|
|
|
Do not use bags or bottles
of intravenous solution as a
common source of supply for
multiple patients. |
| |
|
|
Infection control practices
for special lumbar puncture
procedures |
| |
|
|
 |
Wear a surgical mask when placing a
catheter or injecting material into
the spinal canal or subdural space
(i.e., during myelograms, lumbar
puncture and spinal or epidural
anesthesia. |
|
|
|
|
Employee safety |
| |
|
|
 |
Adhere to federal and state
requirements for protection of
healthcare personnel from exposure
to bloodborne pathogens. |
Handwashing is the most important
measure to reduce the transmission
of microorganisms. Hands should be
washed or alcohol based rubs should
be used between patient contacts and
after gloves are removed. Hands
should be washed after contact with
blood, body fluids, secretions,
excretions, and contaminated
equipment. It may be necessary to
wash hands between tasks on the same
patient to prevent
cross-contamination of different
body sites. CDC and Prevention
Guideline for Hand Hygiene in
Healthcare Settings: Recommendations
of the Healthcare Infection Control
Practices Advisory Committee and
HICPAC/SHEA/APIC/IDSA Hand Hygiene
Task Force (CDC, 2003, p. 51).
|
Improved adherence to hand
hygiene (i.e. hand washing
or use of alcohol-based hand
rubs) has been shown to
terminate outbreaks in
healthcare facilities, to
reduce transmission of
antimicrobial resistant
organisms (e.g. methicillin
resistant staphylococcus
aureus) and reduce overall
infection rates. |
| |
|
|
CDC is releasing guidelines
to improve adherence to hand
hygiene in healthcare
settings. In addition to
traditional handwashing with
soap and water, CDC is
recommending the use of
alcohol-based hand cleansers
by healthcare personnel for
patient care because they
address some of the
obstacles that healthcare
professionals face when
taking care of patients. |
| |
|
|
Handwashing with soap and
water remains a sensible
strategy for hand hygiene in
non-healthcare settings and
is recommended by CDC and
other experts. |
| |
|
|
When healthcare personnel's
hands are visibly soiled,
they should wash with soap
and water. |
| |
|
|
The use of gloves does not
eliminate the need for hand
hygiene. Likewise, the use
of hand hygiene does not
eliminate the need for
gloves. Gloves reduce hand
contamination by 70% to 80
%, prevent cross
contamination and protect
patients and healthcare
personnel from infection.
Hand rubs should be used
before and after each
patient just as gloves
should be changed before and
after each patient. |
| |
|
|
When using an alcohol-based
hand rub, apply product to
palm of one hand and rub
hands together, covering all
surfaces of hands and
fingers, until hands are
dry. Note that the volume
needed to reduce the number
of bacteria on hands varies
by product. |
| |
|
|
Alcohol-based hand rubs
significantly reduce the
number of microorganisms on
skin, are fast acting and
cause less skin irritation. |
| |
|
|
Healthcare personnel should
avoid wearing artificial
nails and keep natural nails
less than one quarter of an
inch long if they care for
patients at high risk of
acquiring infections (e.g.
Patients in intensive care
units or in transplant
units). |
| |
|
|
When evaluating hand hygiene
products for potential use
in healthcare facilities,
administrators or product
selection committees should
consider the relative
efficacy of antiseptic
agents against various
pathogens and the
acceptability of hand
hygiene products by
personnel. Characteristics
of a product that can affect
acceptance and therefore
usage include its smell,
consistency, color and the
effect of dryness on hands. |
| |
|
|
As part of these
recommendations, CDC is
asking healthcare facilities
to develop and implement a
system for measuring
improvements in adherence to
these hand hygiene
recommendations. Some of the
suggested performance
indicators include periodic
monitoring of hand hygiene
adherence and providing
feedback to personnel
regarding their performance,
monitoring the volume of
alcohol-based hand rub
used/1000 patient days,
monitoring adherence to
policies dealing with
wearing artificial nails,
and focused assessment of
the adequacy of healthcare
personnel hand hygiene when
outbreaks of infection
occur. |
| |
|
|
Allergic contact dermatitis
due to alcohol hand rubs is
very uncommon. However, with
increasing use of such
products by healthcare
personnel, it is likely that
true allergic reactions to
such products will
occasionally be encountered. |
| |
|
|
Alcohol-based hand rubs take
less time to use than
traditional hand washing. In
an eight-hour shift, an
estimated one hour of an ICU
nurse's time will be saved
by using an alcohol-based
hand rub. |
The appropriate use of personal
protective equipment (PPE) is an
important element of standard
precautions. Gloves provide a
protective barrier between the
patient and the healthcare
professional and prevent gross
contamination of the hands. Gloves
do not replace the need for
handwashing because the gloves may
have small defects, may be torn
during use, and hands may become
contaminated during glove removal.
Masks, goggles, or face shields
should be used to protect the mucous
membranes of the eyes, nose, and
mouth during situations where there
is a likelihood of splashes or
sprays. A surgical mask is worn by
healthcare professionals to provide
protection against large-particle
droplets during close patient
contact. When tuberculosis is known
or suspected, healthcare
professionals should wear an N95
respirator, a high-efficiency
particulate air (HEPA) filter
respirator, or a powered
air-purifying respirator (PAPR).
Gowns are worn to prevent
contamination of clothing and
protect the healthcare
professional’s skin from blood and
body fluid exposure. Impermeable
gowns, leg coverings, boots, or shoe
covers provide more protection when
large quantities of blood or body
fluids may be splashed. Gowns are
also worn as a part of some
transmission based precautions.
Mouthpieces, resuscitation bags, or
other ventilation devices should be
used instead of mouth-to-mouth
resuscitation.
Transmission based precautions and
protective environment (PE) are
terms used to describe protective
measures that need to be employed
for specific groups of patients. An
older term for this was isolation.
Patients requiring transmission
based precautions require a private
room. A negative pressure air
handling system that exhausts to the
outside is required for airborne
precautions. Movement of these
patients should be limited. When
transport is necessary, appropriate
barriers should be used. Masks
should be used for patients who are
in airborne precautions. Patients
infected with the same organism can
share a room. This is called
cohorting.
Airborne Precautions are implemented
for diseases that are transmitted by
microorganisms in airborne droplet
nuclei. Droplet nuclei are tiny
particle residues left when droplets
evaporate. Droplet nuclei remain
suspended in the air and can be
widely dispersed by air currents.
Early identification and triage of
suspected cases of airborne
transmitted diseases should be done
and possibly infectious patients
should be separated from others and
asked to wear a surgical mask.
|
Diseases Requiring Airborne Precautions
(Lippincott, 2004) |
|
Disease |
Precautionary Period |
|
Chickenpox (varicella) |
Until lesions are crusted and no new lesions
appear |
|
Herpes zoster (disseminated) |
Duration of illness |
|
Herpes zoster (localized in immunocompromised
patient) |
Duration of illness |
|
Measles (rubeola) |
Duration of illness |
|
Smallpox |
Duration of illness |
|
Tuberculosis (pulmonary or laryngeal, confirmed
or suspected) |
Depends upon clinical response; patient must be
on effective therapy, be improving clinically
(decreased cough and fever and improved findings
on chest radiograph), and have three consecutive
negative sputum smears collected on different
days, or TB must be ruled out. |
Airborne precautions require a
specially ventilated room with at
least 6 air changes per hour;
negative air pressure relative to
the hallway; and outside exhaust or
HEPA-filtered recirculation. The
door to the room must be kept
closed. The negative air pressure
should be monitored. An N-95 mask or
a powered air-purifying respirator (PAPR)
is used in airborne precautions
|
These masks and respirators
should be labeled and stored
in a paper bag between uses.
|
| |
|
|
These mask and respirators
should be discarded if
soiled or if it no longer
maintains its structural or
functional integrity. |
| |
|
|
The N-95 mask should also be
discarded at the end of each
work shift. |
| |
|
|
The disposable respirator
should be discarded at the
end of 2 weeks. |
When the patient in airborne
precautions has to be moved or
transported, the patient should wear
a surgical mask from the time he
leaves the isolation room, until he
returns.
Droplet precautions are used for
patients known or suspected to be
infected with microorganisms
transmitted by droplets generated
during coughing, sneezing, talking,
or performance of procedures.
|
Diseases Requiring Droplet Precautions
(Lippincott, 2004) |
|
Disease |
Precautionary Period |
|
Invasive Haemophilus influenzae type b disease,
including meningitis, pneumonia, and sepsis |
Until 24 hours after initiation of effective
therapy |
|
Invasive Neisseria meningitidis disease,
including meningitis, pneumonia, epiglottis, and
sepsis |
Until 24 hours after initiation of effective
therapy |
|
Diphtheria (pharyngeal) |
Until off antibiotics and two cultures taken at
least 24 hours apart are negative
|
|
Mycoplasma pneumoniae infection |
Duration of illness |
|
Pertussis |
Until five days after initiation of effective
therapy |
|
Pneumonic plague |
Until 72 hours after initiation of effective
therapy |
|
Streptococcal pharyngitis, pneumonia, or scarlet
fever in infants and young children |
Until 24 hours after initiation of effective
therapy |
|
Adenovirus infection in infants and young
children |
Duration of illness |
|
Influenza |
Duration of illness |
|
Mumps |
For
9 days after onset of swelling |
|
Parvovirus B19 |
Maintain precautions for duration of
hospitalization when chronic disease occurs in
an immunodeficient patient. For patients with
transient aplastic crisis or red-cell crisis,
maintain precautions for 7 days. |
|
Rubella (German measles) |
Until 7 days after onset of rash |
Droplet precautions require a
private room, but no special
ventilation is necessary and the
door may remain open. Masks should
be worn if working within three feet
of the patient. The patient should
be masked if transported.
Contact precautions are used for
patients with known or suspected
infections or colonized with
epidemiologically important
microorganisms that can be
transmitted by direct or indirect
contact.
|
Diseases Requiring Contact Precautions
(Lippincott, 2004) |
|
Disease |
Precautionary Period |
|
Infection or colonization with
multidrug-resistant bacteria |
Until off antibiotics and culture negative
|
|
Clostridium difficile enteric infection |
Duration of illness |
|
Escherichia coli disease, in diapered or
incontinent patient |
Duration of illness |
|
Shigellosis, in diapered or incontinent patient |
Duration of illness |
|
Hepatitis A, in diapered or incontinent patient |
Duration of illness |
|
Rotavirus infection, in diapered or incontinent
patient |
Duration of illness |
|
Respiratory syncytial virus infection, in
infants and young children |
Duration of illness |
|
Parainfluenza virus infection, in diapered or
incontinent patient |
Duration of illness |
|
Enteroviral infection, in diapered or
incontinent patient |
Duration of illness |
|
Scabies |
Until 24 hours after initiation of effective
therapy |
|
Diphtheria (cutaneous) |
Duration of illness |
|
Herpes simplex virus infection (neonatal or
mucutaneous) |
Duration of illness |
|
Impetigo |
Until 24 hours after initiation of effective
therapy |
|
Major abscesses, cellulitis, or decubiti |
Until 24 hours after initiation of effective
therapy |
|
Pediculosis (lice) |
Until 24 hours after initiation of effective
therapy |
|
Rubella, congenital syndrome |
Place infant on precautions during any admission
until 1 year of age, unless nasopharyngeal and
urine culture are negative for virus after age 3
months |
|
Staphylococcal furunculosis in infants and young
children |
Duration of illness |
|
Acute viral (acute hemorrhagic) conjunctivitis |
Duration of illness |
|
Viral hemorrhagic infections (Ebola, Lassa,
Marburg) |
Duration of illness |
|
Zoster (chickenpox, disseminated zoster, or
localized zoster in immunodeficient patient) |
Until all lesions are crusted
Requires airborne precautions |
|
Smallpox |
Duration of illness
Requires airborne precautions |
The patient should be in a private
room. Standard precautions should be
used, and a gown should be worn if
there is likely to be contact with
the patient or environmental
surfaces.
Some facilities may be implementing
special isolation for VRE. This is
an exaggerated form of contact
precautions requiring the use of
gowns and gloves anytime the room is
entered, even if you do not
anticipate patient contact. The
rational is that VRE survives in the
environment for a long time and
contact with any surface may lead to
transmission. This isolation is not
recommended by CDC.
Neutropenic precautions (reverse
isolation) are implemented to
protect immunocompromised patients.
|
Conditions and Treatments Requiring Neutropenic
Precautions
(Lippincott, 2004) |
|
Condition or Treatment |
Precautionary Period |
|
Acquired immunodeficiency syndrome |
Until white blood cell count reaches 1,000/µl or
more or according to facility guidelines |
|
Agranulocytosis |
Until remission |
|
Burns, extensive noninfected |
Until skin surface heals substantially |
|
Dermatitis, noninfected vesicular, bullous, or
eczematous disease (when severe and extensive) |
Until skin surface heals substantially |
|
Immunosuppressive therapy |
Until patient’s immunity is adequate |
|
Lymphomas and leukemia, especially late stages
of Hodgkin’s disease or acute leukemia |
Until clinical improvement is substantial |
Neutropenic precautions require a
private room with positive air
pressure. Other precautions may
range from standard precautions and
limitation of traffic to extensive
precautions using gloves, gowns, and
masks. This varies depending on the
reason for the precautions and the
degree of the patient’s
immunosuppression.
Immunization is one method to reduce
the transmission of communicable
diseases. The following are
recommendations for immunization
based on age and exposure risk (CDC,
2008). Specifics and schedules for
high risk populations and catch-up
immunizations are available at
www.cdc.gov/vaccines/recs/schedules
(CDC, 2009).
|
Immunization Schedule 0-6 Years |
|
Vaccine |
Birth |
1
month |
2
month |
4
month |
6
months |
12
months |
15
months |
18
months |
19-23 months |
2-3
years |
4-6
years |
|
Hepatitis B |
Hep B |
Hep B |
Hep B |
|
Hep B |
|
|
|
|
|
|
|
Rotavirus |
|
|
Rota |
Rota |
Rota |
|
|
|
|
|
|
Dipttheria,
Tetanus Pertusis |
|
|
DtaP |
DtaP |
DtaP |
|
DtaP |
|
|
|
DtaP |
|
haemophilus
influenzae type b |
|
|
Hib |
Hib |
|
|
|
|
|
|
|
|
Pneumococcal |
|
|
PCV |
PCV |
PCV |
|
|
|
|
|
|
|
Inactived Poliovirus |
|
|
IPV |
IPV |
|
|
|
|
|
|
IPV |
|
Influenza |
|
|
|
|
Influenza Yearly up
to age 5 |
Measles, Mumps,
Rubella |
|
|
|
|
|
MMR |
|
|
|
|
MMR |
|
Varicella |
|
|
|
|
|
Varicella |
|
|
|
|
Varicella |
|
Hepatitis A |
|
|
|
|
|
HepA (2 doses at
least 6 months apart) |
|
|
|
Healthcare Personnel Vaccination Recommendations |
|
Vaccine |
|
Hepatitis B |
HepB (3 doses) |
|
Influenza |
TIV
or LAIV annually |
|
MMR |
MMR
if born 1957 or later if no serologic evidence
of immunity or prior vacciniation |
|
Varicella |
varicella vaccine (3 doses) if no serologic
evidence of immunity |
|
Tetanus, Diphtheria, Pertussis |
Tdap one time if younger than 65, Td every 10
years |
|
Meningococcal |
1
dose to microbiologist who are routinely exposed
to N. meningitidis |
Although the environment is a
reservoir for a variety of
microorganisms, it is rarely
implicated in disease transmission
except in the immunocompromised
population. Consistently applied
infection-control strategies and
engineering controls are effective
in preventing opportunistic,
environmentally-related infections
in immunocompromised populations (Sehulster
et al., 2004).
Definitions
|
Contamination is the
presence of microorganisms
on inanimate objects or
substances. |
| |
|
|
Decontamination is the
process of removing
disease-producing
microorganisms and rendering
the object safe for
handling. |
| |
|
|
Cleaning is the removal of
visible soil. |
| |
|
|
Disinfection is the process
that results in the
elimination of many or all
pathogenic microorganisms on
inanimate objects with the
exception of bacterial
endospores. |
| |
|
|
High level disinfection
kills bacteria, mycobacteria
(TB), fungi, viruses, and
some bacterial spores. |
| |
|
|
Intermediate level
disinfection kills bacteria,
mycobacteria, most fungi,
and most viruses. It does
not kill resistant bacterial
spores. |
| |
|
|
Low level disinfection kills
most bacteria, some fungi,
and some viruses. It will
not kill bacterial spores
and is less active against
some gram negative rods like
pseudomonas and mycobacteria. |
| |
|
|
Sterilization is a process
that completely eliminates
or destroys all forms of
microbial life. |
Environmental Recommendations
The following discussion of
environmental recommendations is a
synopsis of the most recent CDC
recommendations (Rutala & Weber,
2008, pg 83-93).
Recommendations for disinfection
and Sterilization in Healthcare
Facilities
Occupational Health and Exposure
|
Inform each professional of
the possible health effects
of his or her exposure to
infectious agents (e.g.,
hepatitis B virus [HBV],
hepatitis C virus, human
immunodeficiency virus
[HIV]), and/or chemicals
(e.g., EtO, formaldehyde).
The information should be
consistent with Occupational
Safety and Health
Administration (OSHA)
requirements and identify
the areas and tasks in which
potential exists for
exposure. |
| |
|
|
Educate health-care
professionals in the
selection and proper use of
personal protective
equipment (PPE). |
| |
|
|
Ensure that professionals
wear appropriate PPE to
preclude exposure to
infectious agents or
chemicals through the
respiratory system, skin, or
mucous membranes of the
eyes, nose, or mouth. PPE
can include gloves, gowns,
masks, and eye protection.
The exact type of PPE
depends on the infectious or
chemical agent and the
anticipated duration of
exposure. The employer is
responsible for making such
equipment and training
available. |
| |
|
|
Establish a program for
monitoring occupational
exposure to regulated
chemicals (e.g.,
formaldehyde, EtO) that
adheres to state and federal
regulations. |
| |
|
|
Exclude healthcare
professionals with weeping
dermatitis of hands from
direct contact with
patient-care equipment.
|
Cleaning of Patient-Care Devices
|
In hospitals, perform most
cleaning, disinfection, and
sterilization of
patient-care devices in a
central processing
department in order to more
easily control quality.
|
| |
|
|
Meticulously clean
patient-care items with
water and detergent, or with
water and enzymatic cleaners
before high-level
disinfection or
sterilization procedures.
|
| |
|
|
Remove visible organic
residue (e.g., residue of
blood and tissue) and
inorganic salts with
cleaning. Use cleaning
agents that are capable of
removing visible organic and
inorganic residues. |
| |
|
|
 |
Clean medical devices as soon as
practical after use (e.g., at the
point of use) because soiled
materials become dried onto the
instruments. Dried or baked
materials on the instrument make the
removal process more difficult and
the disinfection or sterilization
process less effective or
ineffective. |
|
|
|
|
Perform either manual
cleaning (i.e., using
friction) or mechanical
cleaning (e.g., with
ultrasonic cleaners,
washer-disinfector,
washer-sterilizers). |
| |
|
|
If using an automatic
washer/disinfector, ensure
that the unit is used in
accordance with the
manufacturer’s
recommendations. |
| |
|
|
Ensure that the detergents
or enzymatic cleaners
selected are compatible with
the metals and other
materials used in medical
instruments. Ensure that the
rinse step is adequate for
removing cleaning residues
to levels that will not
interfere with subsequent
disinfection/sterilization
processes. |
| |
|
|
Inspect equipment surfaces
for breaks in integrity that
would impair either cleaning
or
disinfection/sterilization.
Discard or repair equipment
that no longer functions as
intended or cannot be
properly cleaned, and
disinfected or sterilized.
|
Indications for Sterilization,
High-Level Disinfection, and
Low-Level Disinfection
|
Before use on each patient,
sterilize critical medical
and surgical devices and
instruments that enter
normally sterile tissue or
the vascular system or
through which a sterile body
fluid flows (e.g., blood).
Provide, at a minimum,
high-level disinfection for
semicritical patient-care
equipment (e.g.,
gastrointestinal endoscopes,
endotracheal tubes,
anesthesia breathing
circuits, and respiratory
therapy equipment) that
touches either mucous
membranes or nonintact skin.
|
| |
|
|
Perform low-level
disinfection for noncritical
patient-care surfaces (e.g.,
bedrails, over-the-bed
table) and equipment (e.g.,
blood pressure cuff) that
touch intact skin |
Selection and Use of Low-Level
Disinfectants for Noncritical
Patient-Care Devices
|
Process noncritical
patient-care devices using a
disinfectant and the
concentration of germicide
|
| |
|
|
Disinfect noncritical
medical devices (e.g., blood
pressure cuff) with an
EPA-registered hospital
disinfectant using the
label’s safety precautions
and use directions. Most
EPA-registered hospital
disinfectants have a label
contact time of 10 minutes.
However, multiple scientific
studies have demonstrated
the efficacy of hospital
disinfectants against
pathogens with a contact
time of at least 1 minute.
By law, all applicable label
instructions on
EPA-registered products must
be followed. If the user
selects exposure conditions
that differ from those on
the EPA-registered product
label, the user assumes
liability from any injuries
resulting from off-label use
and is potentially subject
to enforcement action under
FIFRA. |
| |
|
|
Ensure that, at a minimum,
noncritical patient-care
devices are disinfected when
visibly soiled and on a
regular basis (such as after
use on each patient or once
daily or once weekly).
|
| |
|
|
If dedicated, disposable
devices are not available,
disinfect noncritical
patient-care equipment after
using it on a patient who is
on contact precautions
before using this equipment
on another patient. |
Cleaning and Disinfecting
Environmental Surfaces in Healthcare
Facilities
|
Clean housekeeping surfaces
(e.g., floors, tabletops) on
a regular basis, when spills
occur, and when these
surfaces are visibly soiled.
|
| |
|
|
Disinfect (or clean)
environmental surfaces on a
regular basis (e.g., daily,
three times per week) and
when surfaces are visibly
soiled. |
| |
|
|
Follow manufacturers’
instructions for proper use
of disinfecting (or
detergent) products, such as
recommended use-dilution,
material compatibility,
storage, shelf-life, and
safe use and disposal.
|
| |
|
|
Clean walls, blinds, and
window curtains in
patient-care areas when
these surfaces are visibly
contaminated or soiled.
|
| |
|
|
Prepare disinfecting (or
detergent) solutions as
needed and replace these
with fresh solution
frequently (e.g., replace
floor mopping solution every
three patient rooms, change
no less often than at
60-minute intervals),
according to the facility’s
policy. |
| |
|
|
Decontaminate mop heads and
cleaning cloths regularly to
prevent contamination (e.g.,
launder and dry at least
daily). |
| |
|
|
Use a one-step process and
an EPA-registered hospital
disinfectant designed for
housekeeping purposes in
patient care areas where 1)
uncertainty exists about the
nature of the soil on the
surfaces (e.g., blood or
body fluid contamination
versus routine dust or
dirt); or 2) uncertainty
exists about the presence of
multidrug resistant
organisms on such surfaces.
See 5n for recommendations
requiring cleaning and
disinfecting
blood-contaminated surfaces.
|
| |
|
|
Detergent and water are
adequate for cleaning
surfaces in nonpatient-care
areas (e.g., administrative
offices). |
| |
|
|
Do not use high-level
disinfectants/liquid
chemical sterilants for
disinfection of non-critical
surfaces. |
| |
|
|
Wet-dust horizontal surfaces
regularly (e.g., daily,
three times per week) using
clean cloths moistened with
an EPA-registered hospital
disinfectant (or detergent).
Prepare the disinfectant (or
detergent) as recommended by
the manufacturer. |
| |
|
|
Disinfect noncritical
surfaces with an
EPA-registered hospital
disinfectant according to
the label’s safety
precautions and use
directions. Most
EPA-registered hospital
disinfectants have a label
contact time of 10 minutes.
However, many scientific
studies have demonstrated
the efficacy of hospital
disinfectants against
pathogens with a contact
time of at least 1 minute.
By law, the user must follow
all applicable label
instructions on
EPA-registered products. If
the user selects exposure
conditions that differ from
those on the EPA-registered
product label, the user
assumes liability for any
injuries resulting from
off-label use and is
potentially subject to
enforcement action under
FIFRA. Do not use
disinfectants to clean
infant bassinets and
incubators while these items
are occupied. If
disinfectants (e.g.,
phenolics) are used for the
terminal cleaning of infant
bassinets and incubators,
thoroughly rinse the
surfaces of these items with
water and dry them before
these items are reused.
Promptly clean and
decontaminate spills of
blood and other potentially
infectious materials.
Discard blood-contaminated
items in compliance with
federal regulations. |
| |
|
|
For site decontamination of
spills of blood or other
potentially infectious
materials (OPIM), implement
the following procedures.
Use protective gloves and
other PPE (e.g., when sharps
are involved use forceps to
pick up sharps, and discard
these items in a
puncture-resistant
container) appropriate for
this task. Disinfect areas
contaminated with blood
spills using an
EPA-registered
tuberculocidal agent, a
registered germicide on the
EPA Lists D and E (i.e.,
products with specific label
claims for HIV or HBV or
freshly diluted hypochlorite
solution. |
| |
|
|
If sodium hypochlorite
solutions are selected use a
1:100 dilution (e.g., 1:100
dilution of a 5.25-6.15%
sodium hypochlorite provides
525-615 ppm available
chlorine) to decontaminate
nonporous surfaces after a
small spill (e.g., <10 mL)
of either blood or OPIM. If
a spill involves large
amounts (e.g., >10 mL) of
blood or OPIM, or involves a
culture spill in the
laboratory, use a 1:10
dilution for the first
application of hypochlorite
solution before cleaning in
order to reduce the risk of
infection during the
cleaning process in the
event of a sharp injury.
Follow this decontamination
process with a terminal
disinfection, using a 1:100
dilution of sodium
hypochlorite. |
| |
|
|
If the spill contains large
amounts of blood or body
fluids, clean the visible
matter with disposable
absorbent material, and
discard the contaminated
materials in appropriate,
labeled containment. |
| |
|
|
Use protective gloves and
other PPE appropriate for
this task. |
| |
|
|
In units with high rates of
endemic Clostridium
difficile infection or in an
outbreak setting, use dilute
solutions of 5.25%–6.15%
sodium hypochlorite (e.g.,
1:10 dilution of household
bleach) for routine
environmental disinfection.
Currently, no products are
EPA-registered specifically
for inactivating C.
difficile spores. |
| |
|
|
If chlorine solution is not
prepared fresh daily, it can
be stored at room
temperature for up to 30
days in a capped, opaque
plastic bottle with a 50%
reduction in chlorine
concentration after 30 days
of storage (e.g., 1000 ppm
chlorine [approximately a
1:50 dilution] at day 0
decreases to 500 ppm
chlorine by day 30). |
| |
|
|
An EPA-registered sodium
hypochlorite product is
preferred, but if such
products are not available,
generic versions of sodium
hypochlorite solutions
(e.g., household chlorine
bleach) can be used. |
Disinfectant Fogging
|
Do not perform disinfectant
fogging for routine purposes
in patient-care areas.
|
| |
|
High-Level Disinfection of
Endoscopes
|
To detect damaged
endoscopes, test each
flexible endoscope for leaks
as part of each reprocessing
cycle. Remove from clinical
use any instrument that
fails the leak test, and
repair this instrument.
|
| |
|
|
Immediately after use,
meticulously clean the
endoscope with an enzymatic
cleaner that is compatible
with the endoscope. Cleaning
is necessary before both
automated and manual
disinfection. |
| |
|
|
Disconnect and disassemble
endoscopic components (e.g.,
suction valves) as
completely as possible and
completely immerse all
components in the enzymatic
cleaner. Steam sterilize
these components if they are
heat stable. |
| |
|
|
Flush and brush all
accessible channels to
remove all organic (e.g.,
blood, tissue) and other
residue. Clean the external
surfaces and accessories of
the devices by using a soft
cloth or sponge or brushes.
Continue brushing until no
debris appears on the brush.
|
| |
|
|
Use cleaning brushes
appropriate for the size of
the endoscope channel or
port (e.g., bristles should
contact surfaces). Cleaning
items (e.g., brushes, cloth)
should be disposable or, if
they are not disposable,
they should be thoroughly
cleaned and either
high-level disinfected or
sterilized after each use.
|
| |
|
|
Discard enzymatic cleaners
(or detergents) after each
use because they are not
microbicidal and, therefore,
will not retard microbial
growth. |
| |
|
|
Process endoscopes (e.g.,
arthroscopes, cystoscope,
laparoscopes) that pass
through normally sterile
tissues using a
sterilization procedure
before each use; if this is
not feasible, provide at
least high-level
disinfection. High-level
disinfection of arthroscopes,
laparoscopes, and cytoscopes
should be followed by a
sterile water rinse. |
| |
|
|
Phase out endoscopes that
are critical items (e.g.,
arthroscopes, laparoscopes)
but cannot be steam
sterilized. Replace these
endoscopes with steam
sterilizable instruments
when feasible. |
| |
|
|
Mechanically clean reusable
accessories inserted into
endoscopes (e.g., biopsy
forceps or other cutting
instruments) that break the
mucosal barrier (e.g.,
ultrasonically clean biopsy
forceps) and then sterilize
these items between each
patient. |
| |
|
|
Use ultrasonic cleaning of
reusable endoscopic
accessories to remove soil
and organic material from
hard-to-clean areas. |
| |
|
|
Process endoscopes and
accessories that contact
mucous membranes as
semicritical items, and use
at least high-level
disinfection after use on
each patient. |
| |
|
|
Use an FDA-cleared sterilant
or high-level disinfectant
for sterilization or
high-level disinfection
|
| |
|
|
After cleaning, use
formulations containing
glutaraldehyde,
glutaraldehyde with phenol/phenate,
ortho-phthalaldehyde,
hydrogen peroxide, and both
hydrogen peroxide and
peracetic acid to achieve
high-level disinfection
followed by rinsing and
drying (see Table 1 for
recommended concentrations).
|
| |
|
|
Extend exposure times beyond
the minimum effective time
for disinfecting
semicritical patient-care
equipment cautiously and
conservatively because
extended exposure to a
high-level disinfectant is
more likely to damage
delicate and intricate
instruments such as flexible
endoscopes. The exposure
times vary among the Food
and Drug Administration
(FDA)-cleared high-level
disinfectants. |
| |
|
|
Federal regulations are to
follow the FDA-cleared label
claim for high-level
disinfectants. The
FDA-cleared labels for
high-level disinfection with
>2% glutaraldehyde at 25oC
range from 20-90 minutes,
depending upon the product
based on three tier testing
which includes AOAC
sporicidal tests, simulated
use testing with
mycobacterial and in-use
testing. |
| |
|
|
Several scientific studies
and professional
organizations support the
efficacy of >2%
glutaraldehyde for 20
minutes at 20ºC; that
efficacy assumes adequate
cleaning prior to
disinfection, whereas the
FDA-cleared label claim
incorporates an added margin
of safety to accommodate
possible lapses in cleaning
practices. Facilities that
have chosen to apply the 20
minute duration at 20ºC have
done so based on the IA
recommendation in the July
2003 SHEA position paper,
“Multi-society Guideline for
Reprocessing Flexible
Gastrointestinal Endoscopes
|
| |
|
|
When using FDA-cleared
high-level disinfectants,
use manufacturers’
recommended exposure
conditions. Certain products
may require a shorter
exposure time (e.g., 0.55%
ortho-phthalaldehyde for 12
minutes at 20oC, 7.35%
hydrogen peroxide plus 0.23%
peracetic acid for 15
minutes at 20oC) than
glutaraldehyde at room
temperature because of their
rapid inactivation of
mycobacteria or reduced
exposure time because of
increased mycobactericidal
activity at elevated
temperature (e.g., 2.5%
glutaraldehyde at 5 minutes
at 35oC). |
| |
|
|
Select a disinfectant or
chemical sterilant that is
compatible with the device
that is being reprocessed.
Avoid using reprocessing
chemicals on an endoscope if
the endoscope manufacturer
warns against using these
chemicals because of
functional damage (with or
without cosmetic damage).
|
| |
|
|
Completely immerse the
endoscope in the high-level
disinfectant, and ensure all
channels are perfused. As
soon as is feasible, phase
out nonimmersible
endoscopes. |
| |
|
|
After high-level
disinfection, rinse
endoscopes and flush
channels with sterile water,
filtered water, or tapwater
to prevent adverse effects
on patients associated with
disinfectant retained in the
endoscope (e.g.,
disinfectant induced
colitis). Follow this water
rinse with a rinse with 70%
- 90% ethyl or isopropyl
alcohol. |
| |
|
|
After flushing all channels
with alcohol, purge the
channels using forced air to
reduce the likelihood of
contamination of the
endoscope by waterborne
pathogens and to facilitate
drying. |
| |
|
|
Hang endoscopes in a
vertical position to
facilitate drying. |
| |
|
|
Store endoscopes in a manner
that will protect them from
damage or contamination.
|
| |
|
|
Sterilize or high-level
disinfect both the water
bottle used to provide
intraprocedural flush
solution and its connecting
tube at least once daily.
After sterilizing or
high-level disinfecting the
water bottle, fill it with
sterile water. |
| |
|
|
Maintain a log for each
procedure and record the
following: patient’s name
and medical record number
(if available), procedure,
date, endoscopist, system
used to reprocess the
endoscope (if more than one
system could be used in the
reprocessing area), and
serial number or other
identifier of the endoscope
used. |
| |
|
|
Design facilities where
endoscopes are used and
disinfected to provide a
safe environment for
healthcare professionals and
patients. Use air-exchange
equipment (e.g., the
ventilation system,
out-exhaust ducts) to
minimize exposure of all
persons to potentially toxic
vapors (e.g., glutaraldehyde
vapor). Do not exceed the
allowable limits of the
vapor concentration of the
chemical sterilant or
high-level disinfectant
(e.g., those of ACGIH and
OSHA). |
| |
|
|
Routinely test the liquid
sterilant/high-level
disinfectant to ensure
minimal effective
concentration of the active
ingredient. Check the
solution each day of use (or
more frequently) using the
appropriate chemical
indicator (e.g.,
glutaraldehyde chemical
indicator to test minimal
effective concentration of
glutaraldehyde) and document
the results of this testing.
Discard the solution if the
chemical indicator shows the
concentration is less than
the minimum effective
concentration. Do not use
the liquid sterilant/high-level
disinfectant beyond the
reuse-life recommended by
the manufacturer (e.g., 14
days for
ortho-phthalaldehyde).
|
| |
|
|
Provide personnel assigned
to reprocess endoscopes with
device-specific reprocessing
instructions to ensure
proper cleaning and
high-level disinfection or
sterilization. Require
competency testing on a
regular basis (e.g.,
beginning of employment,
annually) of all personnel
who reprocess endoscopes.
|
| |
|
|
Educate all personnel who
use chemicals about the
possible biologic, chemical,
and environmental hazards of
performing procedures that
require disinfectants.
|
| |
|
|
Make PPE (e.g., gloves,
gowns, eyewear, face mask or
shields, respiratory
protection devices)
available and use these
items appropriately to
protect professionals from
exposure to both chemicals
and microorganisms (e.g.,
HBV). |
| |
|
|
If using an automated
endoscope reprocessor (AER),
place the endoscope in the
reprocessor and attach all
channel connectors according
to the AER manufacturer’s
instructions to ensure
exposure of all internal
surfaces to the high-level
disinfectant/chemical
sterilant. |
| |
|
|
If using an AER, ensure the
endoscope can be effectively
reprocessed in the AER.
Also, ensure any required
manual cleaning/disinfecting
steps are performed (e.g.,
elevator wire channel of
duodenoscopes might not be
effectively disinfected by
most AERs). |
| |
|
|
Review the FDA advisories
and the scientific
literature for reports of
deficiencies that can lead
to infection because design
flaws and improper operation
and practices have
compromised the
effectiveness of AERs.
|
| |
|
|
Develop protocols to ensure
that users can readily
identify an endoscope that
has been properly processed
and is ready for patient
use. |
| |
|
|
Do not use the carrying case
designed to transport clean
and reprocessed endoscopes
outside of the healthcare
environment to store an
endoscope or to transport
the instrument within the
healthcare environment.
|
| |
|
|
No recommendation is made
about routinely performing
microbiologic testing of
either endoscopes or rinse
water for quality assurance
purposes. |
| |
|
|
If environmental
microbiologic testing is
conducted, use standard
microbiologic techniques.
|
| |
|
|
If a cluster of
endoscopy-related infections
occurs, investigate
potential routes of
transmission (e.g.,
person-to-person, common
source) and reservoirs.
|
| |
|
|
Report outbreaks of
endoscope-related infections
to persons responsible for
institutional infection
control and risk management
and to FDA. Notify the local
and the state health
departments, CDC, and the
manufacturer(s). |
| |
|
|
No recommendation is made
regarding the reprocessing
of an endoscope again
immediately before use if
that endoscope has been
processed after use
according to the
recommendations in this
guideline. |
| |
|
|
Compare the reprocessing
instructions provided by
both the endoscope’s and the
AER’s manufacturer’s
instructions and resolve any
conflicting recommendations.
|
Management of Equipment and
Surfaces in Dentistry
|
Dental instruments that
penetrate soft tissue or
bone (e.g., extraction
forceps, scalpel blades,
bone chisels, periodontal
scalers, and surgical burs)
are classified as critical
and should be sterilized
after each use or discarded.
In addition, after each use,
sterilize dental instruments
that are not intended to
penetrate oral soft tissue
or bone (e.g., amalgam
condensers, air-water
syringes) but that might
contact oral tissues and are
heat-tolerant, although
classified as semicritical.
Clean and, at a minimum,
high-level disinfect
heat-sensitive semicritical
items. |
| |
|
|
Noncritical clinical contact
surfaces, such as uncovered
operatory surfaces (e.g.,
countertops, switches, light
handles), should be
barrier-protected or
disinfected between patients
with an
intermediate-disinfectant
(i.e., EPA-registered
hospital disinfectant with a
tuberculocidal claim) or
low-level disinfectant
(i.e., EPA-registered
hospital disinfectant with
HIV and HBV claim). |
| |
|
|
Barrier protective coverings
can be used for noncritical
clinical contact surfaces
that are touched frequently
with gloved hands during the
delivery of patient care,
that are likely to become
contaminated with blood or
body substances, or that are
difficult to clean. Change
these coverings when they
are visibly soiled, when
they become damaged, and on
a routine basis (e.g.,
between patients). Disinfect
protected surfaces at the
end of the day or if visibly
soiled. |
| |
|
|
Processing Patient-Care
Equipment Contaminated with
Bloodborne Pathogens (HBV,
Hepatitis C Virus, HIV),
Antibiotic-Resistant
Bacteria (e.g., Vancomycin-Resistant
Enterococci, Methicillin-Resistant
Staphylococcus aureus,
Multidrug Resistant
Tuberculosis), or Emerging
Pathogens (e.g.,
Cryptosporidium,
Helicobacter pylori,
Escherichia coli O157:H7,
Clostridium difficile,
Mycobacterium tuberculosis,
Severe Acute Respiratory
Syndrome Coronavirus), or
Bioterrorist Agents |
| |
|
|
Use standard sterilization
and disinfection procedures
for patient-care equipment
(as recommended in this
guideline), because these
procedures are adequate to
sterilize or disinfect
instruments or devices
contaminated with blood or
other body fluids from
persons infected with
bloodborne pathogens or
emerging pathogens, with the
exception of prions. No
changes in these procedures
for cleaning, disinfecting,
or sterilizing are necessary
for removing bloodborne and
emerging pathogens other
than prions. |
Disinfection Strategies for Other
Semicritical Devices
|
Even if probe covers have
been used, clean and
high-level disinfect other
semicritical devices such as
rectal probes, vaginal
probes, and cryosurgical
probes with a product that
is not toxic to staff,
patients, probes, and
retrieved germ cells (if
applicable). Use a
high-level disinfectant at
the FDA-cleared exposure
time. |
| |
|
|
When probe covers are
available, use a probe cover
or condom to reduce the
level of microbial
contamination. Do not use a
lower category of
disinfection or cease to
follow the appropriate
disinfectant recommendations
when using probe covers
because these sheaths and
condoms can fail. |
| |
|
|
After high-level
disinfection, rinse all
items. Use sterile water,
filtered water or tapwater
followed by an alcohol rinse
for semicritical equipment
that will have contact with
mucous membranes of the
upper respiratory tract
(e.g., nose, pharynx,
esophagus). |
| |
|
|
There is no recommendation
to use sterile or filtered
water rather than tapwater
for rinsing semicritical
equipment that contact the
mucous membranes of the
rectum (e.g., rectal probes,
anoscope) or vagina (e.g.,
vaginal probes). |
| |
|
|
Wipe clean tonometer tips
and then disinfect them by
immersing for 5-10 minutes
in either 5000 ppm chlorine
or 70% ethyl alcohol. None
of these listed disinfectant
products are FDA-cleared
high-level disinfectants.
|
Microbial Contamination of
Disinfectants
|
Institute the following
control measures to reduce
the occurrence of
contaminated disinfectants:
1) prepare the disinfectant
correctly to achieve the
manufacturer’s recommended
use-dilution; and 2) prevent
common sources of extrinsic
contamination of germicides
(e.g., container
contamination or surface
contamination of the
healthcare environment where
the germicide are prepared
and/or used). |
Flash Sterilization
|
Do not flash sterilize
implanted surgical devices
unless doing so is
unavoidable. |
| |
|
|
Do not use flash
sterilization for
convenience, as an
alternative to purchasing
additional instrument sets,
or to save time. |
| |
|
|
When using flash
sterilization, make sure the
following parameters are
met: 1) clean the item
before placing it in the
sterilizing container (that
are FDA cleared for use with
flash sterilization) or
tray; 2) prevent exogenous
contamination of the item
during transport from the
sterilizer to the patient;
and 3) monitor sterilizer
function with mechanical,
chemical, and biologic
monitors. |
| |
|
|
Do not use packaging
materials and containers in
flash sterilization cycles
unless the sterilizer and
the packaging
material/container are
designed for this use.
|
| |
|
|
When necessary, use flash
sterilization for
patient-care items that will
be used immediately (e.g.,
to reprocess an
inadvertently dropped
instrument). |
| |
|
|
When necessary, use flash
sterilization for processing
patient-care items that
cannot be packaged,
sterilized, and stored
before use. |
Methods of Sterilization
|
Steam is the preferred
method for sterilizing
critical medical and
surgical instruments that
are not damaged by heat,
steam, pressure, or
moisture. |
| |
|
|
Cool steam or
heat-sterilized items before
they are handled or used in
the operative setting.
|
| |
|
|
Follow the sterilization
times, temperatures, and
other operating parameters
(e.g., gas concentration,
humidity) recommended by the
manufacturers of the
instruments, the sterilizer,
and the container or wrap
used, and that are
consistent with guidelines
published by government
agencies and professional
organizations. |
| |
|
|
Use low-temperature
sterilization technologies
(e.g., EtO, hydrogen
peroxide gas plasma) for
reprocessing critical
patient-care equipment that
is heat or moisture
sensitive. |
| |
|
|
Completely aerate surgical
and medical items that have
been sterilized in the EtO
sterilizer (e.g.,
polyvinylchloride tubing
requires 12 hours at 50oC, 8
hours at 60oC) before using
these items in patient care.
|
| |
|
|
Sterilization using the
peracetic acid immersion
system can be used to
sterilize heat-sensitive
immersible medical and
surgical items. |
| |
|
|
Critical items that have
been sterilized by the
peracetic acid immersion
process must be used
immediately (i.e., items are
not completely protected
from contamination, making
long-term storage
unacceptable). |
| |
|
|
Dry-heat sterilization
(e.g., 340oF for 60 minutes)
can be used to sterilize
items (e.g., powders, oils)
that can sustain high
temperatures. |
| |
|
|
Comply with the sterilizer
manufacturer’s instructions
regarding the sterilizer
cycle parameters (e.g.,
time, temperature,
concentration). |
| |
|
|
Because narrow-lumen devices
provide a challenge to all
low-temperature
sterilization technologies
and direct contact is
necessary for the sterilant
to be effective, ensure that
the sterilant has direct
contact with contaminated
surfaces (e.g., scopes
processed in peracetic acid
must be connected to channel
irrigators). |
Packaging
|
Ensure that packaging
materials are compatible
with the sterilization
process and have received
FDA 510[k] clearance. |
| |
|
|
Ensure that packaging is
sufficiently strong to
resist punctures and tears
to provide a barrier to
microorganisms and moisture.
|
Monitoring of Sterilizers
|
Use mechanical, chemical,
and biologic monitors to
ensure the effectiveness of
the sterilization process.
|
| |
|
|
Monitor each load with
mechanical (e.g., time,
temperature, pressure) and
chemical (internal and
external) indicators. If the
internal chemical indicator
is visible, an external
indicator is not needed.
|
| |
|
|
Do not use processed items
if the mechanical (e.g.,
time, temperature, pressure)
or chemical (internal and/or
external) indicators suggest
inadequate processing.
|
| |
|
|
Use biologic indicators to
monitor the effectiveness of
sterilizers at least weekly
with an FDA-cleared
commercial preparation of
spores (e.g., Geobacillus
stearothermophilus for
steam) intended specifically
for the type and cycle
parameters of the
sterilizer. |
| |
|
|
After a single positive
biologic indicator used with
a method other than steam
sterilization, treat as
nonsterile all items that
have been processed in that
sterilizer, dating from the
sterilization cycle having
the last negative biologic
indicator to the next cycle
showing satisfactory
biologic indicator results.
These nonsterile items
should be retrieved if
possible and reprocessed.
|
| |
|
|
After a positive biologic
indicator with steam
sterilization, objects other
than implantable objects do
not need to be recalled
because of a single positive
spore test unless the
sterilizer or the
sterilization procedure is
defective as determined by
maintenance personnel or
inappropriate cycle
settings. If additional
spore tests remain positive,
consider the items
nonsterile and recall and
reprocess the items from the
implicated load(s). |
| |
|
|
Use biologic indicators for
every load containing
implantable items and
quarantine items, whenever
possible, until the biologic
indicator is negative.
|
Load Configuration
|
Place items correctly and
loosely into the basket,
shelf, or cart of the
sterilizer so as not to
impede the penetration of
the sterilant. |
Storage of Sterile Items
|
Ensure the sterile storage
area is a well-ventilated
area that provides
protection against dust,
moisture, insects, and
temperature and humidity
extremes. |
| |
|
|
Store sterile items so the
packaging is not compromised
(e.g., punctured, bent).
|
| |
|
|
Label sterilized items with
a load number that indicates
the sterilizer used, the
cycle or load number, the
date of sterilization, and,
if applicable, the
expiration date. |
| |
|
|
The shelf life of a packaged
sterile item depends on the
quality of the wrapper, the
storage conditions, the
conditions during transport,
the amount of handling, and
other events (moisture) that
compromise the integrity of
the package. If
event-related storage of
sterile items is used, then
packaged sterile items can
be used indefinitely unless
the packaging is
compromised. |
| |
|
|
Evaluate packages before use
for loss of integrity (e.g.,
torn, wet, punctured). The
pack can be used unless the
integrity of the packaging
is compromised. |
| |
|
|
If the integrity of the
packaging is compromised
(e.g., torn, wet, or
punctured), repack and
reprocess the pack before
use. |
| |
|
|
If time-related storage of
sterile items is used, label
the pack at the time of
sterilization with an
expiration date. Once this
date expires, reprocess the
pack. |
Quality Control
|
Provide comprehensive and
intensive training for all
staff assigned to reprocess
semicritical and critical
medical/surgical instruments
to ensure they understand
the importance of
reprocessing these
instruments. |
| |
|
|
Compare the reprocessing
instructions (e.g., for the
appropriate use of endoscope
connectors, the capping/noncapping
of specific lumens) provided
by the instrument
manufacturer and the
sterilizer manufacturer and
resolve any conflicting
recommendations by
communicating with both
manufacturers. |
| |
|
|
Conduct infection control
rounds periodically (e.g.,
annually) in high-risk
reprocessing areas (e.g.,
the Gastroenterology Clinic,
Central Processing); ensure
reprocessing instructions
are current and accurate and
are correctly implemented.
Document all deviations from
policy. All stakeholders
should identify what
corrective actions will be
implemented. |
| |
|
|
Include the following in a
quality control program for
sterilized items: a
sterilizer maintenance
contract with records of
service; a system of process
monitoring; air-removal
testing for prevacuum steam
sterilizers; visual
inspection of packaging
materials; and traceability
of load contents. |
| |
|
|
For each sterilization
cycle, record the type of
sterilizer and cycle used;
the load identification
number; the load contents;
the exposure parameters
(e.g., time and
temperature); the operator’s
name or initials; and the
results of mechanical,
chemical, and biological
monitoring. |
| |
|
|
Retain sterilization records
(mechanical, chemical, and
biological) for a time
period that complies with
standards (e.g., 3 years),
statutes of limitations, and
state and federal
regulations. |
| |
|
|
Prepare and package items to
be sterilized so that
sterility can be achieved
and maintained to the point
of use. Consult the
Association for the
Advancement of Medical
Instrumentation or the
manufacturers of surgical
instruments, sterilizers,
and container systems for
guidelines for the density
of wrapped packages. |
| |
|
|
Periodically review policies
and procedures for
sterilization. |
| |
|
|
Perform preventive
maintenance on sterilizers
by qualified personnel who
are guided by the
manufacturer’s instruction. |
Reuse of Single-Use Medical
Devices
|
Adhere to the FDA
enforcement document for
single-use devices
reprocessed by hospital. FDA
considers the hospital using
the same standards by which
it regulates the original
equipment manufacturer.
|
Disinfection in Ambulatory Care,
Home Care, and the Home (Rutala &
Weber, 2008, pg 27-28)
|
The home environment should
be much safer than hospitals
or ambulatory care.
Epidemics should not be a
problem, and cross-infection
should be rare. The
healthcare provider is
responsible for providing
the responsible family
member information about
infection-control procedures
to follow in the home,
including hand hygiene,
proper cleaning and
disinfection of equipment,
and safe storage of cleaned
and disinfected devices.
|
| |
|
|
Among the products
recommended for home
disinfection of reusable
objects are bleach, alcohol,
and hydrogen peroxide. APIC
recommends that reusable
objects (e.g., tracheostomy
tubes) that touch mucous
membranes be disinfected by
immersion in 70% isopropyl
alcohol for 5 minutes or in
3% hydrogen peroxide for 30
minutes. Additionally, a
1:50 dilution of 5.25%–6.15%
sodium hypochlorite
(household bleach) for 5
minutes should be effective.
|
| |
|
|
Noncritical items (e.g.,
blood pressure cuffs,
crutches) can be cleaned
with a detergent. Blood
spills should be handled
according to OSHA
regulations. In general,
sterilization of critical
items is not practical in
homes but theoretically
could be accomplished by
chemical sterilants or
boiling. |
| |
|
|
Single-use disposable items
can be used or reusable
items sterilized in a
hospital. |
| |
|
|
Some environmental groups
advocate “environmentally
safe” products as
alternatives to commercial
germicides in the home-care
setting. These alternatives
(e.g., ammonia, baking soda,
vinegar, Borax, liquid
detergent) are not
registered with EPA and
should not be used for
disinfecting because they
are ineffective against S.
aureus. Borax, baking soda,
and detergents also are
ineffective against
Salmonella Typhi and E.coli;
however, undiluted vinegar
and ammonia are effective
against S. Typhi and E.coli.
Common commercial
disinfectants designed for
home use also are effective
against selected
antibiotic-resistant
bacteria. |
| |
|
|
Public concerns have been
raised that the use of
antimicrobials in the home
can promote development of
antibiotic-resistant
bacteria. This issue is
unresolved and needs to be
considered further through
scientific and clinical
investigations. |
| |
|
|
The public health benefits
of using disinfectants in
the home are unknown.
However, some facts are
known: many sites in the
home kitchen and bathroom
are microbially
contaminated, use of
hypochlorites markedly
reduces bacteria, and good
standards of hygiene (e.g.,
food hygiene, hand hygiene)
can help reduce infections
in the home. In addition,
laboratory studies indicate
that many commercially
prepared household
disinfectants are effective
against common pathogens and
can interrupt
surface-to-human
transmission of pathogens.
The “targeted hygiene
concept”—which means
identifying situations and
areas (e.g.,
food-preparation surfaces
and bathroom) where risk
exists for transmission of
pathogens—may be a
reasonable way to identify
when disinfection might be
appropriate. |
Medical equipment should come with
manufacturer instructions on how to
provide care and maintenance. The
instructions should include a) the
equipments’ compatibility with
chemical germicides, b) whether the
equipment is water-resistant or can
be safely immersed for cleaning, and
c) how the equipment should be
decontaminated if servicing is
required (Sehulster et al., 2004).
If manufacturers’ instructions are
not available for non-critical
medical equipment, like stethoscopes
and blood pressure cuffs, they
usually only require cleansing
followed by low- to
intermediate-level disinfection,
depending on the nature and degree
of contamination (Sehulster et al.,
2004).
Cleaning disinfecting and
sterilizing patient care items
should be done in a central location
to control the quality. If
disinfecting and sterilizing is done
in outside the central processing
location, the same level of
efficiency and safety should be
maintained (Rutala & Weber, 2008).
The following principles about
sterilization or disinfection of
patient-care equipment are put forth
by CDC (2002, pg 1).
General Principles
|
In general, reusable medical
devices or patient-care
equipment that enters
normally sterile tissue or
the vascular system or
through which blood flows
should be sterilized before
each use. Sterilization
means the use of a physical
or chemical procedure to
destroy all microbial life,
including highly resistant
bacterial endospores. The
major sterilizing agents
used in hospitals are a)
moist heat by steam
autoclaving, b) ethylene
oxide gas, and c) dry heat.
However, there are a variety
of chemical germicides (sterilants)
that have been used for
purposes of reprocessing
reusable heat-sensitive
medical devices and appear
to be effective when used
appropriately, i.e.,
according to manufacturer's
instructions. These
chemicals are rarely used
for sterilization, but
appear to be effective for
high-level disinfection of
medical devices that come
into contact with mucous
membranes during use (e.g.,
flexible fiberoptic
endoscopes). |
| |
|
|
Heat stable reusable medical
devices that enter the blood
stream or enter normally
sterile tissue should always
be reprocessed using
heat-based methods of
sterilization (e.g., steam
autoclave or dry heat oven).
|
| |
|
|
Laparoscopic or arthroscopic
telescopes (optic portions
of the endoscopic set)
should be subjected to a
sterilization procedure
before each use; if this is
not feasible, they should
receive high-level
disinfection. Heat stable
accessories to the
endoscopic set (e.g.,
trocars, operative
instruments) should be
sterilized by heat-based
methods (e.g., steam
autoclave or dry heat oven).
|
| |
|
|
Reusable devices or items
that touch mucous membranes
should, at a minimum,
receive high-level
disinfection between
patients. These devices
include reusable flexible
endoscopes, endotracheal
tubes, anesthesia breathing
circuits, and respiratory
therapy equipment. |
| |
|
|
Medical devices that require
sterilization or
disinfection must be
thoroughly cleaned to reduce
organic material or
bioburden before being
exposed to the germicide and
the germicide and the device
manufacturer's instructions
should be closely followed.
|
| |
|
|
Except on rare and special
instances (as mentioned
below), items that do not
ordinarily touch the patient
or touch only intact skin
are not involved in disease
transmission, and generally
do not necessitate
disinfection between uses on
different patients. These
items include crutches,
bedboards, blood pressure
cuffs, and a variety of
other medical accessories.
Consequently, depending on
the particular piece of
equipment or item, washing
with a detergent or using a
low-level disinfectant may
be sufficient when
decontamination is needed.
If noncritical items are
grossly soiled with blood or
other body fluids, a higher
level of disinfections is
required. |
Exceptional circumstances that
require noncritical items to be
either dedicated to one patient or
patient cohort or subjected to
low-level disinfection between
patient uses are those involving:
|
Patients infected or
colonized with vancomycin-resistant
enterococci or other
drug-resistant
microorganisms judged by the
infection control program,
based on current state,
regional, or national
recommendations, to be of
special or clinical or
epidemiologic significance
|
or
|
Patients infected with
highly virulent
microorganisms, e.g.,
viruses causing hemorrhagic
fever (such as Ebola or
Lassa) . |
The manufacturer should be contacted
for questions about disinfectants. A
source of information about low
level or intermediate level
disinfectants is the Antimicrobial
Program Branch, Environmental
Protection Agency (EPA) hotline
(703) 308-0127 or email:
info_antimicrobial@epa.gov. A
source of information about high
level disinfectants if the Food and
Drug Administration (FDA) regional
office or the FDA Center for Devices
and Radiological Health at (301)
443-4690 (CDC, 2002).
Construction activities in or near
healthcare facilities cause increase
disease risks for airborne and
waterborne disease. The increasing
age of healthcare facilities is
generating ongoing need for repair
and remediation work that can
introduce or increase contamination
of the air and water in patient-care
environments (Sehulster et al.,
2004). The CDC has further
recommendations for constructions
that should be reviewed if
applicable (CDC, 2003).
The purpose of heating, ventilation,
and air conditioning (HVAC) systems
in healthcare facilities is to a)
maintain the indoor air temperature
and humidity at comfortable levels;
b) control odors; c) remove
contaminated air; d) facilitate
air-handling requirements to provide
protection from airborne
healthcare–related pathogens; and e)
minimize the risk for transmission
of airborne pathogens (Sehulster et
al., 2004). Decreased performance of
healthcare facility HVAC systems,
filter inefficiencies, improper
installation, and poor maintenance
can contribute to the spread of
healthcare–related airborne
infections. The CDC has further
recommendations for HVAC systems
that should be reviewed if
applicable (CDC, 2003).
The following are risk factors for
healthcare-associated bacterial
pneumonia (Tablan, Anderson, Besser,
Bridges, & Haijeh, 2003, pg 11).
|
Risk Factors |
Examples |
|
Factors that enhance colonization of the
oropharynx and/or stomach by microorganisms |
Administration of antimicrobial agents
Admission to the ICU
Presence of underlying chronic lung disease |
|
Conditions favoring aspiration into the
respiratory tract or reflux from the
gastrointestinal tract |
Initial or repeat endotracheal intubation
Insertion of nasogastric tube
Supine position
Coma
Surgical procedures involving the head, neck,
thorax, or upper abdomen
Immobilization due to trauma or illness |
|
Conditions requiring prolonged use of mechanical
ventilatory support with potential exposure to
contaminated respiratory devices and/or contact
with contaminated or colonized hands |
|
|
Host factors |
Extremes of age
Malnutrition
Severe underlying conditions
Immunosuppression |
The following are CDC
recommendations for the prevention
of healthcare associated pneumonia (Tablan,
et. al., 2003, pp 57-96)
| |
|
|
Staff Education |
| |
|
|
Conduct Surveillance in ICU
Patients |
| |
|
|
 |
Do not routinely perform
surveillance cultures of patient,
equipment or devices |
|
|
|
|
Prevention of Transmission
in a Healthcare Setting |
| |
|
|
 |
Sterilization or disinfection: |
|
|
|
|
Thoroughly clean all equipment. When
possible use steam sterilization or
high level disinfection by wet heat
pasteurization |
|
|
|
|
Use sterile water for rinsing
reusable semicritical respiratory
equipment after chemical
disinfection. If this not feasible,
rinse with filtered water. |
|
|
|
|
Adhere to provisions in the FDA/s
enforcement document for single use
devices that are reprocess by third
parties. |
|
|
|
|
Periodically drain and discard any
condensate, making sure the
condensate does not drain toward the
patient. |
|
|
|
|
Wear gloves during procedure or
handling of condensate |
|
|
|
|
Decontaminate hands with soap and
water if visible soiled or with
alcohol-based hand rub after
procedure. |
|
|
|
|
No recommendation can be made for
placing a filter or trap at the
distal end of the expiratory-phase
tubing to collect condensate. |
|
|
|
|
No recommendation can be made for
the preferential use of either HMEs
or heated humidifiers to prevent
pneumonia in patients receiving
mechanically assisted ventilation
|
|
|
|
|
Change an HME that is in use on a
patient when it malfunctions
mechanically or becomes visibly
soiled. |
|
|
|
|
Do not routinely change an HME that
is in use on a patient more
frequently than every 48 hours. |
|
|
|
|
Do not routinely change the
breathing circuit attached to an HME
while it is in use on a patient
|
|
|
|
|
 |
Oxygen humidifiers |
|
|
|
|
Follow manufacturers' instructions
for use of oxygen humidifiers |
|
|
|
|
Change the humidifier-tubing
(including any nasal prongs or mask)
that is in use on one patient when
it malfunctions or becomes visibly
contaminated. |
|
|
|
|
 |
Small-volume medication nebulizers:
in-line and hand-held nebulizers |
|
|
|
|
Between treatments on the same
patient: clean, disinfect; rinse
with sterile water (if rinsing is
needed), and dry small-volume
in-line or hand-held medication
nebulizers |
|
|
|
|
Use only sterile fluid for
nebulization, and dispense the fluid
into the nebulizer aseptically
|
|
|
|
|
Whenever possible, use aerosolized
medications in single-dose vials. If
multidose medication vials are used,
follow manufacturers’ instructions
for handling, storing, and
dispensing the medications |
|
|
|
|
 |
Mist-tents |
|
|
|
|
Between uses on different patients,
replace mist tents and their
nebulizers, reservoirs, and tubings
with those that have been subjected
to sterilization or high-level
disinfection |
|
|
|
|
No recommendation can be made about
the frequency of routinely changing
mist-tent nebulizers, reservoirs,
and tubings while in use on one
patient. |
|
|
|
|
Subject mist-tent nebulizers,
reservoirs and tubings that are used
on the same patient to daily
low-level disinfection (e.g., with
2% acetic acid) or pasteurization
followed by air-drying |
|
|
|
|
 |
Other devices |
|
|
|
|
Between uses on different patients,
sterilize or subject to high level
disinfection: |
|
|
|
|
Portable respirometers, and
ventilator thermometers |
|
|
|
|
Reusable hand-powered resuscitation
bags |
|
|
|
|
No recommendation can be made about
the frequency of changing
hydrophobic filters placed on the
connection port of resuscitation
bags. |
|
|
|
|
 |
Anesthesia machines and breathing
systems or patient circuits: |
|
|
|
|
Do not routinely sterilize or
disinfect the internal machinery of
anesthesia equipment |
|
|
|
|
Between uses on different patients,
clean reusable components of the
breathing system or patient circuit
and then sterilize or subject them
to high-level liquid chemical
disinfection or pasteurization in
accordance with the device
manufacturers' instructions for
their reprocessing |
|
|
|
|
No recommendation can be made about
the frequency of routinely cleaning
and disinfecting unidirectional
valves and carbon dioxide absorber
chambers |
|
|
|
|
Follow published guidelines and
manufacturers' instructions about in
use maintenance, cleaning, and
disinfection or sterilization of
other components or attachments of
the breathing system or patient
circuit of anesthesia equipment
|
|
|
|
|
No recommendation can be made for
placing a bacterial filter in the
breathing system or patient circuit
of anesthesia equipment |
|
|
|
|
 |
Pulmonary-function testing equipment |
|
|
|
|
Do not routinely sterilize or
disinfect the internal machinery of
pulmonary-function testing machines
between uses on different patients
|
|
|
|
|
Change the mouthpiece of a peak flow
meter or the mouthpiece and filter
of a spirometer between uses on
different patients |
|
|
|
|
 |
Room-air “humidifiers” and faucet
aerators |
|
|
|
|
Do not use large-volume room-air
humidifiers that create aerosols
(e.g., by venturi principle,
ultrasound, or spinning disk, and
thus actually are nebulizers) unless
they can be sterilized or subjected
to high-level disinfection at least
daily and filled only with sterile
water |
|
|
|
|
No recommendation can be made about
the removal of faucet aerators from
areas for immunocompetent patients
|
|
|
|
|
If Legionella spp. are detected in
the water of a transplant unit and
until Legionella spp. are no longer
detected by culture, remove faucet
aerators in the unit |
|
|
|
| |
|
|
Standard Precautions |
| |
|
|
Care of patients with
tracheostomy |
| |
|
|
Suctioning of respiratory
tract secretions |
| |
|
|
|
|
|
Increasing Host Defense
Against Infection:
Administration of Immune
Modulators |
| |
|
|
 |
Pneumococcal vaccination. Vaccinate
patients at high risk for severe
pneumococcal infections: |
|
|
|
|
persons aged >65 years; |
|
|
|
|
persons aged 5-64 years who have
chronic cardiovascular disease,
chronic pulmonary disease, diabetes
mellitus, alcoholism, chronic liver
disease (cirrhosis), or cerebro-spinal
fluid (CSF) leaks; |
|
|
|
|
persons aged 5-64 years who have
functional or anatomic asplenia;
|
|
|
|
|
persons aged 5-64 years who are
living in special environments or
social settings; |
|
|
|
|
immunocompromised persons aged >5
years with HIV infection, leukemia,
lymphoma, Hodgkin’s disease,
multiple myeloma, generalized
malignancy, chronic renal failure,
nephrotic syndrome, or other
conditions associated with
immunosuppression and persons in
long-term care facilities |
|
|
|
|
Precautions for Prevention
of Aspiration |
| |
|
|
 |
As soon as the clinical indications
for their use are resolved, remove
devices such as endotracheal,
tracheostomy, or enteral (i.e., oro-
or nasogastric, or jejunal) tubes
from patients |
|
|
|
 |
Prevention of aspiration associated
with endotracheal intubation |
|
|
|
|
Use of NIV to reduce the need for
and duration of endotracheal
intubation |
|
|
|
|
When feasible and not medically
contraindicated, use noninvasive
positive-pressure ventilation
delivered continuously by face or
nose mask, instead of performing
endotracheal intubation in patients
who are in respiratory failure and
are not needing immediate intubation
|
|
|
|
|
When feasible and not medically
contraindicated, use NIV as part of
the weaning process in order to
shorten the period of endotracheal
intubation |
|
|
|
|
As much as possible, avoid repeat
endotracheal intubation in patients
who have received mechanically
assisted ventilation |
|
|
|
|
Unless contraindicated by the
patient’s condition, perform
orotracheal rather than nasotracheal
intubation on patients |
|
|
|
|
If feasible, use an endotracheal
tube with a dorsal lumen above the
endotracheal cuff to allow drainage
(by continuous or frequent
intermittent suctioning) of tracheal
secretions that accumulate in the
patient's subglottic area |
|
|
|
|
Before deflating the cuff of an
endotracheal tube in preparation for
tube removal, or before moving the
tube, ensure that secretions are
cleared from above the tube cuff. |
|
|
|
|
Prevention of aspiration
associated with enteral
feeding: |
| |
|
|
Prevention or modulation of
oropharyngeal colonization |
| |
|
|
No recommendation can be made for
the routine use of an oral
chlorhexidine rinse for the
prevention of healthcare associated
pneumonia in all postoperative or
critically ill patients or other
patients at high risk for pneumonia
|
|
|
|
|
Use an oral chlorhexidine gluconate
(0.12%) rinse during the
perioperative period on adult
patients who undergo cardiac surgery
|
|
|
|
|
 |
No recommendation can be made for
the routine use of topical
antimicrobial agents for oral
decontamination to prevent
ventilator associated pneumonia (VAP) |
|
|
|
|
Prevention of gastric
colonization |
| |
|
| |
|
|
Instruct preoperative
patients, especially those
at high risk for contracting
pneumonia, about taking deep
breaths and ambulating as
soon as medically indicated
in the postoperative period.
Patients at high-risk
include: |
| |
|
|
Encourage all postoperative
patients to take deep
breaths, move about the bed,
and ambulate unless these
are medically
contraindicated |
| |
|
|
Use incentive spirometry on
postoperative patients at
high risk for developing
pneumonia |
| |
|
|
No recommendation can be
made about the routine use
of chest physiotherapy on
all postoperative patients
at high risk for pneumonia |
| |
|
|
Administration of
antimicrobial agents other
than in SDD |
| |
|
|
 |
No recommendation can be made about
the routine administration of
systemic antimicrobial agent(s) to
prevent pneumonia in critically ill
patients and/or in those receiving
mechanically-assisted ventilation
|
|
|
|
 |
No recommendation can be made for
scheduled changes in the class of
antimicrobial agents used routinely
for empiric treatment of suspected
infections in a particular group of
patients |
|
|
|
|
No recommendation can be
made for the routine use of
turning or rotational
therapy, either by "kinetic"
therapy or by continuous
lateral rotational therapy
(i.e., placing patients on
beds that turn on their
longitudinal axes
intermittently or
continuously) for prevention
of healthcare-associated
pneumonia in critically ill
or immobilized patients |
| |
|
|
Staff Education |
| |
|
|
Infection and Environmental
Surveillance |
| |
|
|
 |
Maintain a high index of suspicion
for the diagnosis of healthcare
associated Legionnaires disease and
perform laboratory diagnostic tests
(both culture of appropriate
respiratory specimen and the urine
antigen test) for legionellosis on
suspected cases, especially in
patients who are at high risk of
acquiring the disease |
|
|
|
|
patients who are immunosuppressed,
including HSCT or
solid-organ-transplant recipients;
|
|
|
|
|
patients receiving systemic
steroids; |
|
|
|
|
patients aged >65 years; |
|
|
|
|
or patients who have chronic
underlying disease such as diabetes
mellitus, congestive heart failure,
and COPD) |
|
|
|
|
 |
Periodically review the availability
and clinicians’ use of laboratory
diagnostic tests for Legionnaires
disease in the facility, and if
clinicians do not routinely use the
tests on patients with diagnosed or
suspected pneumonia, implement
measures to enhance clinicians’ use
of the tests (e.g., by conducting
educational programs) |
|
|
|
 |
Routine culturing of water systems
for Legionella spp. |
|
|
|
|
No recommendation can be made about
routinely culturing water systems
for Legionella spp. in healthcare
facilities that do not have
patient-care areas (i.e., transplant
units) for persons at high risk for
Legionella infection |
|
|
|
|
In facilities with hemopoietic
stem-cell- or solid-organ
transplantation programs, periodic
culturing for legionellae in water
samples from the transplant unit(s)
can be performed as part of a
comprehensive strategy to prevent
Legionnaires disease in transplant
recipients |
|
|
|
|
No recommendation can be made about
the optimal methods (i.e.,
frequency, number of sites) for
environmental surveillance cultures
in transplant units. |
|
|
|
|
 |
Perform corrective measures aimed at
maintaining undetectable levels of
Legionella spp. in the unit’s water
system. |
|
|
|
 |
Maintain a high index of suspicion
for legionellosis in transplant
patients with healthcare-associated
pneumonia even when environmental
surveillance cultures do not yield
legionellae |
|
|
|
|
Use and Care of Medical
Devices, Equipment, and
Environment |
| |
|
|
 |
If Legionella spp. are detected in
the water of a transplant unit and
until Legionella spp. are no longer
detected by culture, remove faucet
aerators in areas for severely
immunocompromised patients |
|
|
|
 |
Cooling towers |
|
|
|
|
When a new building is constructed,
place cooling towers in such a way
that the tower drift is directed
away from the facility's air intake
system and design the cooling towers
such that the volume of aerosol
drift is minimized |
|
|
|
|
For cooling towers, install drift
eliminators, regularly use an
effective biocide, maintain the
tower according to manufacturers'
recommendations, and keep adequate
maintenance records |
|
|
|
|
Water-distribution system |
| |
|
|
If legionellae are detected in the
potable water supply of a transplant
unit, and until legionellae are no
longer detected by culture: |
|
|
|
|
Decontaminate the water supply
|
|
|
|
|
Restrict severely immunocompromised
patients from taking showers |
|
|
|
|
Use water that is not contaminated
with Legionella spp. for HSCT
patients’ sponge baths |
|
|
|
|
Provide HSCT patients with sterile
water for tooth brushing or
drinking, or for flushing
nasogastric tubes |
|
|
|
|
Do not use water from faucets with
Legionella-contaminated water in
patients rooms to avoid creating
infectious aerosols |
| |
|
|
Staff Education |
| |
|
|
Case-Reporting, Disease
Surveillance, and
Case-Contact Notification |
| |
|
|
face-to-face contact with a patient
who is symptomatic (e.g., in the
catarrhal or paroxysmal period of
illness). |
|
|
|
|
sharing a confined space in close
proximity for a prolonged period of
time (e.g., >1 hour) with a
symptomatic patient; |
|
|
|
|
or direct contact with respiratory,
oral, or nasal secretions from a
symptomatic patient (e.g., an
explosive cough or sneeze on the
face, sharing food, sharing eating
utensils during a meal, kissing,
mouth-to-mouth resuscitation, or
performing a full medical
examination of the nose and throat)
|
|
|
|
|
Prevention of Pertussis
Transmission |
| |
|
|
 |
Vaccination for Primary Prevention |
|
|
|
|
No recommendation can be made for
routinely vaccinating adults,
including healthcare professionals,
with the acellular pertussis vaccine
at regular intervals (e.g., every 10
years) |
|
|
|
|
In LTCFs for children and for
children with prolonged stay in
acute-care facilities, follow the
recommendations of ACIP for
vaccinating children according to
their chronologic age |
|
|
|
|
 |
Vaccination for Secondary Prevention |
|
|
|
|
No recommendation can be made for
routinely vaccinating adults,
including healthcare professionals,
with the acellular pertussis vaccine
at regular intervals (e.g., every 10
years) |
|
|
|
|
During an institutional outbreak of
pertussis, accelerate scheduled
vaccinations to infants and children
aged <7 years who have not completed
their primary vaccinations, as
follows: |
|
|
|
|
Infants aged <2 months who are
receiving their initial vaccination:
Administer the first dose of the
DTaP vaccine as early as age 6 weeks
and the second and third doses at a
minimum of 4-week intervals between
doses. Give the fourth dose on or
after age 1 year and >6 months after
the third dose |
|
|
|
|
Other children aged <7 years:
Administer DTaP vaccine to all
patients who are aged <7 years and
are not up-to-date with their
pertussis vaccinations, as follows:
administer a fourth dose of DtaP
vaccine if the child has had 3 doses
of DTaP or diphtheria, tetanus and
pertussis (DTP) vaccine, is >12
months old, and >6 months have
passed since the third dose of DTaP
or DTP vaccine; administer a fifth
dose of DTaP vaccine if the child
has had four doses of DTaP or DTP
vaccine, is aged 4-6 years, and
received the fourth vaccine dose
before the fourth birthday |
|
|
|
|
Vaccination of children with a
history of well-documented pertussis
disease |
|
|
|
|
No recommendation can be made for
administering additional dose(s) of
pertussis vaccine to children who
have a history of well-documented
pertussis disease (i.e., pertussis
illness with either a B. pertussis-positive
culture or epidemiologic linkage to
a culture-positive case) |
|
|
|
|
Patient Placement and
Management |
| |
|
|
 |
Patients with confirmed pertussis |
|
|
|
|
Place a patient with diagnosed
pertussis in a private room, or if
known not to have any other
respiratory infection, in a room
with other patient(s) with pertussis
until after the first 5 days of a
full course of antimicrobial
treatment or 21 days after the onset
of cough if unable to take
antimicrobial treatment for
pertussis |
|
|
|
|
 |
Patients with suspected pertussis |
|
|
|
|
Place a patient with suspected
pertussis in a private room. After
pertussis and no other infection is
confirmed, the patient may be placed
in a room with other patient(s) who
have pertussis until after the first
5 days of a full course of
antimicrobial treatment or 21 days
after the onset of cough if unable
to take antimicrobial treatment for
pertussis |
|
|
|
|
Perform diagnostic laboratory tests
(for confirmation or exclusion of
pertussis) on patients who are
admitted with or who develop signs
and symptoms of pertussis to allow
for the earliest possible
downgrading of infection-control
precautions to the minimum required
for each patient’s specific
infection(s) |
|
|
|
|
Management of Symptomatic
Healthcare Personnel |
| |
|
|
Masking |
| |
|
|
 |
In addition to observing standard
precautions, wear a surgical mask
when within three feet of a patient
with confirmed or suspected
pertussis, when performing
procedures or patient-care
activities that are likely to
generate sprays of respiratory
secretions, or on entering the room
of a patient with confirmed or
suspected pertussis |
|
|
|
|
Prophylactic Antibiotic
Regimen for Contacts of
Persons with Pertussis are
recommended |
| |
|
|
Work Exclusion of
Asymptomatic Healthcare
Professionals Exposed to
Pertussis |
| |
|
|
 |
Do not exclude from patient care a
healthcare professional who remains
asymptomatic and is receiving
chemoprophylaxis after an exposure
to a case of pertussis |
|
|
|
 |
If mandated by state law or where
feasible, exclude an exposed,
asymptomatic healthcare professional
who is unable to receive
chemoprophylaxis, from providing
care to a child aged <4 years during
the period starting 7 days after the
professional’s first possible
exposure until 14 days after his
last possible exposure to a case of
pertussis |
|
|
|
|
Other measures |
| |
|
|
 |
Limit the movement and transport of
a patient with diagnosed or
suspected pertussis from his room to
those for essential purposes only.
If the patient is transported out of
the room, ensure that precautions
are maintained to minimize the risk
for disease transmission to other
patients and contamination of
environmental surfaces or equipment
|
|
|
|
 |
Do not allow persons who have
symptoms of respiratory infection to
visit pediatric, immunosuppressed,
or cardiac patients |
| |
|
|
Staff Education |
| |
|
|
Surveillance |
| |
|
|
 |
Maintain a high index of suspicion
for healthcare-associated pulmonary
aspergillosis in severely
immunocompromised patients |
|
|
|
 |
Maintain surveillance for cases of
healthcare-associated pulmonary
aspergillosis by establishing a
system by which the facility’s
infection-control personnel are
promptly informed when Aspergillus
sp. is isolated from cultures of
specimens from patient’s respiratory
tract and by periodically reviewing
the hospital's microbiologic,
histopathologic, and postmortem
data. |
|
|
|
 |
Do not perform routine, periodic
cultures of the nasopharynx of
asymptomatic patients at high risk
|
|
|
|
 |
Do not perform routine, periodic
cultures of equipment or devices
used for respiratory therapy,
pulmonary function testing, or
delivery of inhalation anesthesia in
the HSCT unit, nor of dust in rooms
of HSCT recipients |
|
|
|
 |
No recommendation can be made about
routine microbiologic air sampling
before, during, or after facility
construction or renovation, or
before or during occupancy of areas
housing immunocompromised patients
|
|
|
|
 |
In facilities with PEs, perform
surveillance of the ventilation
status of these areas either by
continuous monitoring or periodic
analysis of the following
parameters: room air exchanges,
pressure relations and filtration
efficacy to ensure that appropriate
levels are |
|
|
|
|
Prevention of Transmission
of Aspergillus spp. Spores |
| |
|
|
 |
Planning New Specialized-Care Units
for High-Risk Patients |
|
|
|
|
When constructing new
specialized-care units with
protected environment (PE) for HSCT
recipients, ensure that patient
rooms have adequate capacity to
minimize accumulation of fungal
spores via 1) HEPA filtration of
incoming air, 2) directed room
airflow, 3) positive air pressure in
patient's room in relation to the
corridor, 4) well-sealed room, and
5) high (>12) air changes per hour
|
|
|
|
|
Do not use LAF routinely in PE
|
|
|
|
|
Units for autologous HSCT and
solid-organ transplant recipients
|
|
|
|
|
No recommendation can be made for
constructing PE for recipients of
autologous HSCTs or
solid-organ-transplants (e.g.,
heart, liver, lung, kidney) |
|
|
|
|
 |
In Existing Facilities with HSCT
Units and No Cases of
Healthcare-Associated Aspergillosis |
|
|
|
|
No recommendation can be made for
routinely placing a recipient of
autologous HSCT or solid-organ
transplant in PE. |
|
|
|
 |
Maintain air-handling systems in PE
and other high-risk patient-care
areas according to published
recommendations |
|
|
|
 |
Develop a water-damage response plan
for immediate execution when water
leaks, spills, and moisture
accumulation occur to prevent fungal
growth in the involved areas |
|
|
|
 |
Use proper dusting methods for
patient-care areas designated for
severely immunocompromised |
|
|
|
 |
Wet-dust horizontal surfaces daily
using cloth that has been moistened
with an EPA-registered hospital
disinfectant |
|
|
|
 |
Avoid dusting methods that disperse
dust (e.g., feather dusting) |
|
|
|
 |
Keep vacuums in good repair and
equip them with HEPA filters for use
in areas with patients at high risk
|
|
|
|
 |
Do not use carpeting in hallways and
rooms occupied by severely
immunocompromised patients |
|
|
|
 |
Avoid using upholstered furniture or
furnishings in rooms occupied by
severely immunocompromised patients. |
|
|
|
 |
Minimize the length of time that
immunocompromised patients in PEs
are outside their rooms for
diagnostic procedures and other
activities. |
|
|
|
 |
Instruct severely immunocompromised
patients to wear a high efficiency
respiratory-protection device (e.g.,
an N95 respirator) when they leave
the PE during periods when
construction, renovation, and/or
other dust-generating activities are
ongoing in and around the healthcare
facility |
|
|
|
 |
No recommendation can be made about
the specific type of
respiratory-protection device (e.g.,
surgical mask, N95 respirator) for
use by a severely immunocompromised
patient who leaves the PE during
periods when there is no
construction, renovation or other
dust-generating activity in progress
in or around the healthcare
facility. |
|
|
|
 |
Systematically review and coordinate
infection-control strategies with
personnel in charge of the
facility’s engineering, maintenance,
central supply and distribution, and
catering services |
|
|
|
 |
When planning construction,
demolition, and renovation
activities in and around the
facility, assess whether patients at
high-risk for aspergillosis are
likely to be exposed to high
ambient-air spore counts of
Aspergillus spp. from construction,
demolition, and renovation sites,
and if so, develop a plan to prevent
such exposures |
|
|
|
 |
During construction, demolition, or
renovation activities, construct
impermeable barriers between
patient-care and construction areas
to prevent dust from entering the
patient-care areas |
|
|
|
 |
Direct pedestrian traffic that come
from construction areas away from
patient-care areas to limit the
opening and closing of doors or
other barriers that might cause dust
dispersion, entry of contaminated
air, or tracking of dust into
patient-care areas |
|
|
|
 |
Do not allow fresh or dried flowers
or potted plants in patient-care
areas for severely immunocompromised
patients |
|
|
|
|
 |
When a Case of Aspergillosis Occurs |
|
|
|
|
Assess whether the infection is
healthcare-related or
community-acquired. |
|
|
|
|
Determine, if any ventilation
deficiency exists in the PEs |
|
|
|
|
If no evidence exists that the
patient’s aspergillosis is
facility-acquired, continue routine
maintenance procedures to prevent
healthcare-associated aspergillosis |
|
|
|
|
If evidence of possible
facility-acquired infection with
Aspergillus spp. exists, conduct an
epidemiologic investigation and an
environmental assessment to
determine and eliminate the source
of Aspergillus spp. |
|
|
|
|
Use an antifungal biocide (e.g.,
copper-8-quinolinolate) that is
registered with the Environmental
Protection Agency for
decontamination of structural
materials |
|
|
|
|
Chemoprophylaxis |
| |
|
|
 |
No recommendation can be made for
the routine administration of
antifungal agents |
|
|
|
 |
No recommendation can be made for
any specific strategy to prevent
recurrence of pulmonary
aspergillosis in patients undergoing
hematopoietic stemcell
transplantation who have a history
of pulmonary aspergillosis |
| |
|
|
Staff Education |
| |
|
|
Surveillance |
| |
|
|
 |
Establish mechanisms by which the
appropriate healthcare personnel are
promptly alerted to any increase in
the activity of RSV, parainfluenza
virus, adenovirus, or other
respiratory viruses in the local
community. Establish mechanisms by
which the appropriate healthcare
personnel can promptly inform the
local and state health departments
of any increase in the activity of
the above-named viruses or of
influenza-like illness in their
facility. |
|
|
|
 |
In acute-care facilities during
periods of increased prevalence of
symptoms of viral respiratory
illness in the community or
healthcare facility, and/or during
the RSV and influenza season (i.e.,
December-March), attempt prompt
diagnosis of respiratory infections
caused by RSV, influenza,
parainfluenza, or other respiratory
viruses. Use rapid diagnostic
techniques as clinically indicated
in patients who are admitted to the
healthcare facility with respiratory
illness and are at high risk for
serious complications from viral
respiratory infections (e.g.,
pediatric patients, especially
infants, and those with compromised
cardiac, pulmonary, or immune
function) |
|
|
|
 |
No recommendation can be made for
routinely conducting surveillance
cultures for RSV or other
respiratory viruses in respiratory
secretions of patients |
|
|
|
 |
In LTCFs, establish mechanism(s) for
continuing surveillance to allow
rapid identification of a potential
outbreak in the facility. |
|
|
|
|
Prevention Of Transmission
Of RSV, Parainfluenza Virus,
Or Adenovirus |
| |
|
|
 |
Prevention of Person-to-Person
Transmission |
|
|
|
|
Standard and contact precautions for
RSV and parainfluenza virus; and
standard, contact, and droplet
precautions for adenovirus |
|
|
|
|
Patient placement in acute-care
facilities |
|
|
|
|
Place a patient with diagnosed RSV,
parainfluenza, adenovirus, or other
viral respiratory tract infection in
a private room when possible or in a
room with other patients with the
same infection and no other
infection |
|
|
|
|
Place a patient with suspected RSV,
parainfluenza, adenovirus, or other
viral respiratory tract infection in
a private room. |
|
|
|
|
Promptly perform rapid diagnostic
laboratory tests on patients who are
admitted with or who have symptoms
of RSV infection after admission to
the healthcare facility to
facilitate early downgrading of
infection-control precautions to the
minimum required for each patient’s
specific viral infection |
|
|
|
|
Promptly perform rapid diagnostic
laboratory tests on patients who are
admitted with or who have symptoms
of parainfluenza or adenovirus
infection after admission to the
healthcare facility to facilitate
early downgrading of
infection-control precautions to the
minimum required for each patient’s
specific viral infection and early
initiation of treatment when
indicated. |
|
|
|
|
 |
Limiting patient movement or
transport in acute-care facilities |
|
|
|
|
Limit to essential purposes only the
movement or transport of patients
from their rooms when they are
diagnosed or suspected to be
infected with RSV, parainfluenza
virus, or |
|
|
|
|
If transport or movement from the
room is necessary |
|
|
|
|
For a patient with diagnosed or
suspected RSV or parainfluenza virus
infection, ensure that precautions
are maintained to minimize the risk
for transmission of the virus to
other patients and contamination of
environmental surfaces or equipment
by ensuring that the patient does
not touch other persons’ hands or
environmental surfaces with hands
that have been contaminated with
his/her respiratory secretions |
|
|
|
|
For a patient with diagnosed or
suspected adenovirus infection,
minimize patient dispersal of
droplets by having the patient wear
a surgical mask, and ensure that
contact precautions are maintained
to minimize the risk of transmission
of the virus to other patients and
contamination of environmental
surfaces or equipment |
|
|
|
|
 |
Other measures in acute-care
facilities |
|
|
|
|
Staffing |
|
|
|
|
Restrict healthcare personnel in the
acute stages of an upper respiratory
tract infection from caring for
infants and other patients at high
risk for complications from viral
respiratory tract infections |
|
|
|
|
When feasible, perform rapid
diagnostic testing on healthcare
personnel with symptoms of
respiratory tract infection,
especially those who provide care to
patients at high-risk for acquiring
and/or developing severe
complications from RSV,
parainfluenza, or adenovirus
infection, so that their work status
can be determined promptly. |
|
|
|
|
Limiting visitors |
|
|
|
|
Do not allow persons who have
symptoms of respiratory infection to
visit pediatric, immunocompromised,
or cardiac patients |
|
|
|
|
Follow the recommendations of the
American Academy of Pediatrics to
consider monthly administration of
palivizumab, an RSV
monoclonal-antibody preparation |
|
|
|
|
Control of outbreaks in
acute-care facilities |
| |
|
| |
|
|
Staff Education |
| |
|
|
Surveillance |
| |
|
|
Modifying Host Risk For
Infection |
| |
|
|
 |
Vaccination |
|
|
|
|
In acute-care settings (including
acute-care hospitals, emergency
rooms, and walk-in clinics) or
ongoing-care facilities (including
physicians’ offices, public health
clinics, employee health clinics,
hemodialysis centers, hospital
specialty-care clinics, outpatient
rehabilitation programs, or mobile
clinics), offer vaccine to
inpatients and outpatients at high
risk for complications from
influenza beginning in September and
throughout the influenza season |
|
|
|
|
Groups at high risk for
influenza-related complications
include |
|
|
|
|
those aged >65 years; |
|
|
|
|
residents of LTCFs that house
persons of any age who have chronic
medical conditions; |
|
|
|
|
adults and children aged >6 months
who have chronic disorders of the
pulmonary or cardiovascular system,
including asthma; |
|
|
|
|
adults and children who have
required regular medical follow-up
or hospitalization during the
preceding year because of chronic
metabolic diseases (including
diabetes mellitus), renal
dysfunction, hemoglobinopathies; or
immunosuppression (including
immunosuppression caused by
medications or HIV); |
|
|
|
|
children and adolescents (aged 6
months-18 years) who are receiving
long-term aspirin therapy; and women
who will be in the second or third
trimester of pregnancy during the
influenza season. |
|
|
|
|
In addition, offer annual influenza
vaccination to all persons aged
50-64 years, close contacts of
children aged <24 months, and
healthy children aged 6-23 months
|
|
|
|
|
In LCTFs, establish an SOP for
timely administration of the
inactivated influenza vaccine to
high-risk persons |
|
Obtain consent for influenza
vaccination (if such is required by
local or state law) from every
resident (or his/her guardian) at
the time the resident is admitted to
the facility or anytime afterwards,
before the next influenza season. |
|
|
|
|
Routinely vaccinate all residents,
except those with medical
contraindication(s) to receipt of
influenza vaccine, (under a standing
operating procedure (SOP) or with
the concurrence of the residents’
respective attending physicians) at
one time, annually, before the
influenza season. To residents who
are admitted during the winter
months after completion of the
facility’s vaccination program,
offer the vaccine at the time of
their admission |
|
|
|
|
In other settings where healthcare
is given (e.g., in homes visited by
personnel from home healthcare
agencies), vaccinate patients for
whom vaccination is indicated, as
listed in section III-A-1, and refer
patient’s household members and care
givers for vaccination, before the
influenza season |
|
|
|
|
Personnel |
|
|
|
|
Beginning in October each year,
provide inactivated influenza
vaccine for all personnel including
night and weekend staff. Throughout
the influenza season, continue to
make the vaccine available to newly
hired personnel and to those who
initially refuse vaccination. If
vaccine supply is limited, give
highest priority to staff caring for
patients at greatest risk for severe
complications from influenza
infection. |
|
|
|
|
Educate healthcare personnel
regarding the benefits of
vaccination and the potential health
consequences of influenza illness
for themselves and their patients
|
|
|
|
|
Take measures to provide all
healthcare personnel convenient
access to inactivated influenza
vaccine at the work site, free of
charge, as part of employee health
program |
|
|
|
|
 |
Prevention of Person to Person
Transmission |
|
|
|
|
Droplet Precautions |
|
|
|
|
Personnel Restrictions |
|
|
|
|
In acute-care facilities, utilize
the facility’s employee health
service or its equivalent to
evaluate personnel with
influenza-like illness and determine
whether they should be removed from
duties that involve direct patient
contact. Use more stringent criteria
for personnel who work in certain
patient-care areas (e.g., ICUs,
nurseries, and organ-transplant
[especially HSCT] units) where
patients who are most susceptible to
influenza-related complications are
located |
|
|
|
|
 |
Control of Influenza Outbreaks |
|
|
|
|
Determine the Outbreak Strain |
|
|
|
|
Vaccination of Patients and
Personnel |
|
|
|
|
Administer current inactivated
influenza vaccine to unvaccinated
patients and healthcare personnel
|
|
|
|
|
Antiviral Agent Administration |
|
|
|
|
When a facility outbreak of
influenza is suspected or
recognized: |
|
|
|
|
Administer amantadine, rimantadine,
or oseltamivir as prophylaxis to all
patients without influenza illness
in the involved unit for whom the
antiviral agent is not
contraindicated (regardless of
whether they received influenza
vaccinations during the previous
fall). Do not delay administration
of the antiviral agent(s) for
prophylaxis unless the results of
diagnostic tests to identify the
infecting strain(s) can be obtained
within 12-24 hours after specimen
collection |
|
|
|
|
Administer amantadine, rimantadine,
oseltamivir, or zanamivir to
patients acutely ill with influenza,
within 48 hours of illness onset. |
|
|
|
|
Choose the agent appropriate for the
type of influenza virus circulating
in the community. Offer antiviral
agent(s) (amantadine, rimantadine,
or oseltamivir) for prophylaxis to
unvaccinated personnel for whom the
antiviral agent is not
contraindicated and who are in the
involved unit or taking care of
patients at high-risk |
|
|
|
|
Consider prophylaxis for all
healthcare personnel, regardless of
their vaccination status, if the
outbreak is caused by a variant of
influenza that is not well matched
by the vaccine |
|
|
|
|
No recommendation can be made about
the prophylactic administration of
zanamivir to patients or personnel |
|
|
|
|
Discontinue the administration of
influenza antiviral agents to
patients or personnel if laboratory
tests confirm or strongly suggest
that influenza is not the cause of
the facility outbreak |
|
|
|
|
If the cause of the outbreak is
confirmed or believed to be
influenza and vaccine has been
administered only recently to
susceptible patients and personnel,
continue prophylaxis with an
antiviral agent until 2 weeks after
the vaccination |
|
|
|
|
To reduce the potential for
transmission of drug-resistant
virus, do not allow contact between
persons at high risk for
complications from influenza and
patients or personnel who are taking
an antiviral agent for treatment of
confirmed or suspected influenza
during and for 2 days after the
latter discontinue treatment |
|
|
|
|
 |
Other Measures in Acute-Care
Facilities: |
|
|
|
|
When influenza outbreaks, especially
those characterized by high attack
rates and severe illness, occur in
the community and/or facility: |
|
|
|
|
Curtail or eliminate elective
medical and surgical admissions
|
|
|
|
|
Restrict cardiovascular and
pulmonary surgery to emergency cases
only |
|
|
|
|
Restrict persons with influenza or
influenza-like illness from visiting
patients in the healthcare facility
|
|
|
|
|
Restrict personnel with influenza or
influenza-like illness from patient
care |
Special attention in dental
facilities is required. Back flow
prevention devices are required to
prevent cross contamination when
using cuspidors, high speed hand
piece and air or water syringes.
Back-siphonage devices are required
to prevent contamination of the
public water. This is regulated by
the health authority or plumbing
code enforcement agencies in the
community (CDC, October, 2008).
Definitions
|
Infectious disease is a
clinically manifest disease
of man or animal resulting
from an infection. |
| |
|
|
Communicable disease is an
illness due to a specific
infectious agent which
arises through transmission
of that agent from an
infected person, animal, or
inanimate reservoir to a
susceptible host. |
| |
|
|
Occupational Health
Strategies, as applied to
infection control, are a set
of activities intended to
assess, prevent, and control
infections and communicable
diseases in healthcare
professionals. |
Safety and health issues can best be
addressed in the setting of a
comprehensive prevention program
that considers all aspects of the
work environment and that has
employee involvement as well as
management commitment. Implementing
the use of improved engineering
controls is one component of such a
comprehensive program. Prevention
strategy factors that must be
addressed include implementation of
needleless systems if possible,
modification of hazardous work
practices, administrative changes to
address needle hazards in the
environment (e.g., prompt removal of
filled sharps disposal boxes),
safety education and awareness,
feedback on safety improvements, and
action taken on continuing problems.
Employers are required to establish
exposure control plans that include
post-exposure follow up for their
employees and to comply with
incident reporting requirements
mandated by the 1992 OSHA bloodborne
pathogen standard. Access to
clinicians who can provide
post-exposure care should be
available during all working hours,
including nights and weekends. HBIG,
hepatitis B vaccine, and
antiretroviral agents for HIV
post-exposure prophylaxis (PEP)
should be available for timely
administration, either by providing
access on site or by creating
linkages with other facilities or
providers to make them available
off-site (CDC, 2001).
The following are recommendation by
the Centers for Disease Control (DHHS,
2003) for immediate activity after
exposure.
Provide immediate care to the
exposure site.
|
Wash wounds and skin with
soap and water. |
| |
|
|
Flush mucous membranes with
water. |
| |
|
|
Irrigate eyes with clean
water, saline or sterile
irrigants. |
No scientific evidence shows that
using antiseptics or squeezing the
wound will reduce the risk of
transmission of a bloodborne
pathogen. Using a caustic agent such
as bleach is not recommended.
Report the exposure to the
government agency responsible for
managing exposures. Reporting is
necessary because PEP treatment may
be recommended.
Determine risk associated with
exposure by:
|
type of fluid (e.g., blood,
visibly bloody fluid, other
potentially infectious fluid
or tissue, and concentrated
virus), and |
| |
|
|
type of exposure (i.e.,
percutaneous injury, mucous
membrane or non-intact skin
exposure, and bites
resulting in blood
exposure). |
Evaluate exposure source.
|
Assess the risk of infection
using available information.
|
| |
|
|
Test known sources for HBsAg,
anti-HCV, and HIV antibody
(consider using rapid
testing). |
| |
|
|
For unknown sources, assess
risk of exposure to HBV, HCV,
or HIV infection. |
| |
|
|
Do not test discarded
needles or syringes for
virus contamination. |
Evaluate the exposed person.
|
Assess immune status for HBV
infection (i.e., by history
of hepatitis B vaccination
and vaccine response).
|
Comprehensive exposure prevention
strategies have played a significant
role in decreasing the probable risk
of infection from bloodborne
pathogens. The risks of exposure
with appropriate precautions are
low, but they are real.
Understanding how an exposure occurs
and the risks of exposure is
imperative for both the occupational
health clinician and the healthcare
professional. After an occupational
exposure to a bloodborne pathogen,
the risk of infection depends on a
number of factors including:
|
type of body substance
involved |
| |
|
|
route of exposure, |
| |
|
|
volume of blood or body
fluid involved |
| |
|
|
severity of exposure, |
| |
|
|
pathogen involved |
| |
|
|
degree of viremia |
| |
|
|
the immune status of the
healthcare professional at
the time of the injury |
| |
|
|
whether appropriate PEP was
used |
HBV: The number of occupational
infections decreased by 95% after
the HBV vaccine became available in
1982 (CDC, January 2003). Healthcare
professionals who have received
hepatitis B vaccine and have
developed immunity to the virus are
at virtually no risk for infection.
The risk of HBV infection is
primarily related to the degree of
contact with blood in the workplace
and also to the hepatitis B e
antigen (HBeAg) status of the source
person. Individuals who are both
hepatitis B surface antigen (HBsAg)
positive and HBeAg positive have
more virus in their blood and are
more likely to transmit HBV. Amongst
healthcare professionals who are
susceptible, the risk of infection
after one percutaneous exposure is
6%-30% (CDC, January 2003).
Although percutaneous injuries are
among the most efficient modes of
HBV transmission, these exposures
probably account for only a minority
of HBV infections among healthcare
professionals. In several
investigations of nosocomial
hepatitis B outbreaks, most infected
healthcare professionals could not
recall an overt percutaneous injury,
although in some studies, up to one
third of the infected recalled
caring for a patient who was HBsAg-positive.
Additionally, HBV has been
demonstrated to survive in dried
blood at room temperature on
environmental surfaces for at least
1 week (CDC, 2001).
HBV infections that occur in
healthcare professionals with no
history of non-occupational exposure
or occupational percutaneous injury
might have resulted from direct or
indirect blood or body fluid
exposures that inoculated HBV into
cutaneous scratches, abrasions,
burns, other lesions, or on mucosal
surfaces (CDC, 2001). HBsAg is also
found in several other body fluids,
including breast milk, bile,
cerebrospinal fluid, feces,
nasopharyngeal washings, saliva,
semen, sweat, and synovial fluid.
However, most body fluids are not
efficient vehicles of transmission
because they contain low quantities
of infectious HBV, despite the
presence of HBsAg (CDC, 2001).
HCV is not transmitted efficiently
through occupational exposures to
blood. Transmission has been
reported rarely, but more than half
the reported cases had other risk
factors (Pearlman, 2004). The risk
for HCV infection after a
needlestick or sharps exposure to
HCV-positive blood is approximately
1.8% (range: 0%–10%) (CDC, Nov.,
2008). Transmission rarely occurs
from mucous membrane exposures to
blood, and no transmission in
healthcare professionals has been
documented from intact or non-intact
skin exposures to blood.
HIV: The average risk of HIV
transmission after a percutaneous
exposure to HIV-infected blood has
been estimated to be approximately
0.3%. The risk after a mucous
membrane exposure is approximately
0.09% (Panlilio, Cardo, Grohskophf,
Heneine, & Ross, 2005). Although
episodes of HIV transmission after
non-intact skin exposure have been
documented, the average risk for
transmission by this route has not
been precisely quantified but is
estimated to be less than the risk
for mucous membrane exposures. The
risk for transmission after exposure
to fluids or tissues other than
HIV-infected blood also has not been
quantified but is probably
considerably lower than for blood
exposures (Panlilio, et.al. 2005).
By calling 1-888-448-4911 from
anywhere in the United States 24
hours a day, clinicians can gain
access to the National Clinicians'
Post-Exposure Prophylaxis Hotline (PEPline).
The PEPline has trained physicians
prepared to give clinicians
information, counseling and
treatment recommendations for
professionals who have needlestick
injuries and other serious
occupational exposures to blood
borne microorganisms that lead to
such serious infections or diseases
as HIV or hepatitis (DHHS, 1999).
HBV: Recommendations for HBV
post-exposure management include
initiation of the hepatitis B
vaccine series to any susceptible,
unvaccinated person who sustains an
occupational blood or body fluid
exposure, regardless of the source
person’s hepatitis B status.
Postexposure Prophylaxis (PEP) with
hepatitis B immune globulin (HBIG)
and/or hepatitis B vaccine series
should be considered for
occupational exposures after
evaluation of the hepatitis B
surface antigen status of the source
and the vaccination and vaccine
response status of the exposed
person (DHHS, 2003).
Women who are pregnant or
breastfeeding can be vaccinated
against HBV infection and/or get
HBIG. Pregnant women who are exposed
to blood should be vaccinated
against HBV infection, because
infection during pregnancy can cause
severe illness in the mother and a
chronic infection in the newborn.
The vaccine does not harm the fetus.
Post-exposure treatment should begin
as soon as possible after exposure,
preferably within 24 hours, and no
later than 7 days. Hepatitis B
immune globulin (HBIG) is effective
in preventing HBV infection after an
exposure. The decision to begin
treatment is based on several
factors, such as (DHHS, 2003):
|
|
_ whether the source individual is
positive for hepatitis B surface
antigen, |
|
|
|
|
|
_ whether the healthcare
professional has been vaccinated,
and |
|
|
|
|
|
_ whether the vaccine provided
immunity |
HCV: There is no vaccine against
hepatitis C and no treatment after
an exposure that will prevent
infection. Immune globulin and
antiviral agents like, Interferon,
with or without ribavirin, are not
recommended for PEP of hepatitis C.
IG is not effective for postexposure
prophylaxis of HCV. Antiviral agents
(e.g., interferon) are not
recommended to prevent HCV
infection. The mechanisms of the
effect of interferon in treating HCV
are not understood, and an
established infection might need to
be present for interferon to be
effective.
Limited data indicate that antiviral
therapy might be beneficial when
started early in the course of HCV
infection, but no guidelines exist
for administration of therapy during
the acute phase of infection. When
HCV infection is identified early,
the individual should be referred
for medical management to a
specialist in this area.
HIV: There is no vaccine against
HIV. PEP is not recommended for all
occupational exposures to HIV
because most exposures do not lead
to HIV infection and because the
drugs used to prevent infection may
have serious side effects. Based on
the level of risk of HIV
transmission of the exposure, a two
or more drug PEP may be recommended.
A three or more drug regimen may be
recommended for an exposure of high
risk transmission, but potential
toxicity many prevent completion of
the regimen, making the regimen
ineffective (Panlilio, Cardo,
Grohskophf, Heneine, & Ross, 2005).
The PEP regimen should be started
immediately. The optimal duration of
PEP is not known.
The majority of HIV exposures
warrant a two drug regime using two
nucleoside reverse transcriptase
inhibitors (NRTIs), or one NRTI and
one nucleotide reverse transcriptase
inhibitors (NtRTIs). Because of the
complexity determining PEP,
consultation should be sought. The
following are resources for
consultation (Panlilio, et.al, 2005,
pg 10):
All of the antiviral drugs for HIV
have been associated with side
effects. The most common side
effects include nausea, vomiting,
diarrhea, tiredness, or headache.
The few serious side effects that
have been reported in healthcare
professionals using combination PEP
have included kidney stones,
hepatitis, and suppressed blood cell
production. Interaction with other
medicines can cause serious side
effects.
Pregnancy should not rule out the
use of post-exposure treatment when
it is warranted. However, what is
known and not known regarding the
potential benefits and risks
associated with the use of antiviral
drugs in order to make an informed
decision about treatment. The effect
of antiretroviral drugs on
developing fetus may be teratogenic
(Panlilio, et.al, 2005).
If the source individual cannot be
identified or tested, decisions
regarding follow-up should be based
on the exposure risk and whether the
source is likely to be a person who
is infected with a bloodborne
pathogen. Follow-up testing should
be available to all professionals
who are concerned about possible
infection through occupational
exposure.
HBV: If the HBV vaccine is given, a
follow up test in 1-2 months will
determine the response to the
vaccine. Other routine follow-up
after post-exposure treatment is not
recommended, because the prevention
is highly effective. Symptoms
suggesting hepatitis should be
reported (DHHS, 2003).
|
|
Postexposure follow-up of healthcare, emergency
medical and public safety professionals for HCV
virus (CDC, Nov., 2008): |
|
For
the source |
Perform baseline testing for anti-HCV |
|
For
the person exposed to an HCV-positive source |
Perform baseline and follow-up testing,
including baseline testing for anti-HCV and ALT
activity
AND
Follow-up testing for anti-HCV (e.g., at 4–6
months) and ALT activity. If earlier diagnosis
of HCV infection is desired, testing for HCV RNA
may be performed at 4–6 weeks |
|
|
Supplemental anti-HCV testing to confirm all
anti-HCV results reported as positive by enzyme
immunoassay |
“CDC's recommendations for
prevention and control of HCV
infection specify that persons
should not be excluded from work,
school, play, child care, or other
settings on the basis of their HCV
infection status. There is no
evidence of HCV transmission from
food handlers, teachers, or other
service providers in the absence of
blood-to-blood contact” (CDC, Nov.,
2008, pg.1).
HIV: Follow up counseling,
postexposure testing, and medical
evaluation should be done regardless
of whether PEP was used (Panlilio,
et.al. 2005). Perform HIV-antibody
testing by enzyme immunoassay should
be monitored at baseline, six weeks,
12 weeks, and six months. If the
exposed person becomes infected with
HCV, HIV testing should be done for
12 months (Panlilio, et.al, 2005).
People on PEP should be monitored
closely for toxicity.
HBV: If the exposed healthcare
professional receives post-exposure
treatment, it is unlikely that
infection and exposure to others
will occur. No precautions are
recommended (DHHS, 2003).
HCV: Because the risk of becoming
infected and passing the infection
on to others after an exposure to
HCV is low, no precautions are
recommended.
HIV: During the follow-up period,
especially the first 6-12 weeks when
most infected persons are expected
to show signs of infection, the
exposed person should follow
recommendations for preventing
transmission of HIV. These include
not donating blood, semen, or organs
and not having sexual intercourse.
If the healthcare professional
chooses to have sexual intercourse,
using a condom consistently and
correctly may reduce the risk of HIV
transmission. In addition, women
should consider not breastfeeding
infants during the follow-up period
to prevent exposing their infants to
HIV in breast milk.
Healthcare professionals have an
obligation to adhere to
scientifically accepted standards
for infection control and
responsibility to monitor the
infection control practices of
subordinates. The correct
incorporation of work practice
controls and engineering controls
help to avoid or reduce exposure to
potentially infectious materials and
hazards. Compliance with
environmental infection control
measures will decrease the risk of
healthcare related infections among
patients, especially the
immunocompromised and healthcare
professionals (Sehulster et al.,
2004).
Bauldoff, G., Kirkpatrick, B.
Sheets, D., Mays, B., & Curran, C.
(2008). Implementation of Handheld
Devices. Nurse Educator. 33(6),
November/December 2008. pp 244-248.
Retrieved 1/2/09 from
http://ovidsp.tx.ovid.com/spb/ovidweb.cgi?&S=ILEIFPBNDNDDNKNONCGLBFJJMFGGAA00&Link+Set=S.sh.15%7c9%7csl_10
CDC. (2008). Recommended
Immunization Schedule for Persons
Aged 0-6 Years-United States. CDC.
Retrieved 1/2/09 from
http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2008/08_0-6yrs_schedule_pr.pdf
CDC. (2008). Recommended
Immunization Schedule for Persons
Aged 7-18 Years-United States. CDC.
Retrieved 1/2/09 from
http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2008/08_7-18yrs_schedule_pr.pdf
CDC. (2008). Healthcare Personnel
Vaccination Recommendations. CDC.
Retrieved 1/2/09 from
http://www.immunize.org/catg.d/p2017.pdf
CDC. (2008). Recommended Adult
Immunization Schedule. CDC.
Retrieved 1/2/09 from
http://www.cdc.gov/vaccines/recs/schedules/downloads/adult/07-08/adult-schedule.pdf
CDC. (November, 2008). Hepatitis C
Virus Infection, Past or Present.
Retrieved 11/15/08 from
http://www.cdc.gov/ncphi/disss/nndss/casedef/hepatitisccurrent.htm
CDC. (October, 2008). Infection
Control in Dental Settings. October
29, 2008. Retrieved 1/2/19 from
http://www.cdc.gov.
CDC. (May, 2008). Injection Safety.
(May 16, 2008). Retrieved 1/2/09
from
http://www.cdc.gov/ncidod/dhqp/injectionSafetyPractices.html.
CDC. (April, 2008). Vancomycin-resistant
Enterococci (VRE). April 30, 2008.
Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/ar_vre.html
CDC. (October, 2007). MRSA in
Healthcare Settings. October 3,
2007. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/ar_MRSA_spotlight_2006.html.
CDC. (July, 2007). Drug-resistant
Tuberculosis in Healthcare Settings.
July 9, 2007. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/ar_tb.html
CDC. (May, 2006). Infectious
Diseases in Healthcare Settings. May
22, 2006. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/id.html.
CDC. (September, 2005).
Ventilator-Associated Pneumonia.
September 27, 2005. Retrieved 1/2/09
from
http://www.cdc.gov/ncidod/dhqp/dpac_ventilate.html
CDC. (April, 2005). Viral
Hemorrhagic Fever (VHF) in
Healthcare Setting (April, 1, 2005.
Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/bp_vhf.html.
CDC. (April, 2004). VISA/VRSA:
Vancomycin-Intermediate/ Resistant
Staphylococcus aureus. April 21,
2004. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/ar_visavrsa.html.
CDC. (September, 2004). Drug
resistant Acinetobacter Infections
in Healthcare Settings. Retrieved
1/2/09 from
http://www.cdc.gov/ncidod/dhqp/ar_acinetobacter.html.
CDC. (2003). Guidelines for
environmental infection control in
healthcare facilities:
Recommendations of CEC and the
Healthcare Infection Control
Practices Advisory Committee (HICPAC).
Morbidity and Mortality Weekly
Report, 52(RR10)1-42. Retrieved
January 10, 2005 from
www.cdc.gov.
CDC. (July, 2003). Exposure to
Blood, what Healthcare Personnel
Need to Know. (July 2003). Retrieved
1/2/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/bbp/Exp_to_Blood.pdf.
CDC. (January, 2003). Overview of
Hepatitis B in Healthcare Settings.
January 27, 2003. Retrieved 2/16/09
from
http://www.cdc.gov/ncidod/dhqp/bp_hepatitisb.html.
CDC. (August, 2002). Sterilization
or Disinfection of Medical Devices.
(August 20, 2002). Retrieved 1/2/09
from
http://www.cdc.gov/ncidod/dhqp/bp_sterilization_medDevices.html.
CDC. (August 2, 2001).Parents Guide
to Childhood Immunization, National
Immunization Publication, Retrieved
December 10, 2005 from
http://www.cdc.gov/nip/publications/Parents-Guide/default.htm.
CDC. (June 29, 2001). Updated U.S.
Public Health Service guidelines for
the management of occupational
exposures to HBV, HCV. Retrieved
January 10, 2005 from
www.cdc.gov.
CDC. (January 2001) Drug-resistant
S. pneumoniae in Healthcare
Settings. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/ar_spneumoniae.html.
DesRoches, P. & Moore, P. (2003).
HIV post-exposure prophylaxis (PEP)
- Effect on management of bloodborne
pathogen exposures in the healthcare
environment. AAOHN Journal. 51(9) p
370.
DHHS. (2003). Exposure to Blood:
What Healthcare Personnel need to
Know. The Public Health Foundation.
July 2003. Retrieved 2/16/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/bbp/Exp_to_Blood.pdf.
Foster, K., & Clark, A. (2008).
Increasing Hand Hygiene compliance:
A Mystery? Clinical Nurse
Specialist. 22(6), November/December
2008 pp 263-267. Retrieved 1/2/09
from
http://ovidsp.tx.ovid.com/spb/ovidweb.cgi?&S=ILEIFPBNDNDDNKNONCGLBFJJMFGGAA00&Link+Set=S.sh.15|6|sl_10.
Griffith, D. (2004). Treatment of
multidrug-resistant Tuberculosis:
Should you try this at home?
American Journal of Respiratory and
Critical Care Medicine. 169(10),
1082-1084.
Kroger. A., Atkinson, W., Marcuse,
E., Pickering, L. (2006). General
Recommendations on Immunization.
Centers for Disease Control MMWR,
December 1, 2006/55(RR15):1-48.
Retrieved 1/2/09 from
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm?s_cid=rr5515a1_e.
Lippincott Procedures Version 2.2.
(2004). Lippincott, Williams, &
Wilkins. Retrieved December 10, 2005
from
http://vaww.north-florida.med.va.gov/procedures/mainMenu.do.
Murray, J. (2004). A century of
Tuberculosis. American Journal of
Respiratory and Critical Care
Medicine. 169(11) m 1181-1187.
NIOSH. (1999). Alert: Preventing
needlestick injuries in healthcare
settings. DSSH NIOSH publication
2000-108. Retrieved January 10, 2005
from
http://www.cdc.gov/niosh/pdfs/2000-108.pdf
Nettina, S. (2001). The Lippincott
Manual of Nursing Practice (7th
ed.). Lippincott. Philadelphia.
New York State Education Department
(1992). Unprofessional conduct in
the area of infection control. Rules
of the Board of Regents Section
29.2(a) (13),
New York State (2008). Department of
Health, Healthcare Provider
Infection Control Training.
Retrieved 1/2/09 from
http://www.health.state.ny.us/professionals/diseases/reporting/communicable/infection/hcp_training.htm
Panlilio, A., Cardo, d., Grohskophf,
L., Heneine, W., & Ross, C. (2005).
Updated U.S. Public Health Service
Guidelines for the Management of
Occupational Exposures to HIV and
Recommendations for Postexposure
Prophylaxis. Center for Disease
Control MMWR, September 30,
2005/54(RR09); 1-17. Retrieved
1/2/09 from
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm.
Pearlman, B. (2004). Hepatitis C
infection: A clinical review.
Southern Medical Journal. 97(4),
365-376.
Perry, J. Jagger, J. & Parker G.
(2003). Nurses and needlesticks,
then and now. Nursing. 33(4), p. 22.
Pinkerton, S., Martin, J., Roland,
M., Katz, M. et al. (2004).
Cost-effectiveness of post-exposure
prophylaxis after sexual or
injection-drug exposure to human
immunodeficiency virus. Archives of
Internal Medicine. 164(1). P 46-56.
Rutala, W. & Weber, D. (2008).
Guideline for Disinfection and
Sterilization in Healthcare
Facilities, 2008. Center for Disease
Control. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Disinfection_Nov_2008.pdf.
Sehulster, L., et al. (2004).
Guidelines for environmental
infection control in healthcare
facilities. Retrieved December 10,
2005 from
www.APIC.org.
Smeltzer, S. & Bare, B. (2003).
Burnner and Suddarth’s textbook of
medical-surgical nursing (10th ed.).
Lippincott, Philadelphia.
Siegel, J., Rhinehart, E., Jackson,
M. & Chiarello, L. (2007). Guideline
for Isolation Precautions:
Preventing Transmission of
Infectious Ageing in Healthcare
Settings 2007. Center for Disease
Control. Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf.
Siegel, J., Rhinehart, E., Jackson,
M. & Chiarello, L. (2006).
Management of Multidrug-Resistant
Organisms in Healthcare Settings,
2006. Center for Disease Control.
Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/ar/MDROGuideline2006.pdf.
Sunenshine, R. & McDonald, L.
(2006). Clostridium difficile-associated
Disease: New Challenges from an
Established Pathogen. Cleveland
Clinic Journal of Medicine.
72/2.number 2. pg 187-197 Retrieved
1/2/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/infDis/Cdiff_CCJM02_06.pdf.
Tablan, O., Anderson, L. Besser, R.,
Bridges, C., & Haijeh, R. (2003).
Guidelines for Preventing
Healthcare-Associated Pneumonia.
Center for Disease Control.
Retrieved 1/2/09 from
http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/CDCpneumo_guidelines.pdf. |